
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="utf-8"?-->


     <title></title>
<meta http-equiv="Content-Type" content="text/html">

<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_hltt_healthtechsol.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001307624 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->

<div style="display: none">
<ix:header>
 <ix:hidden>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey" inside-table="false" id="fact-identifier-0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001307624</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag" inside-table="false" id="fact-identifier-1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalYearFocus" inside-table="false" id="fact-identifier-2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span>
  <span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentFiscalPeriodFocus" inside-table="false" id="fact-identifier-3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span>
  <ix:nonfraction id="xdx2ixbrl0244" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0250" unitref="Shares" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0262" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0263" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0265" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0268" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0269" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0270" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0285" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0293" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0295" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0303" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0304" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0311" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0313" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0318" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0319" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0321" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0324" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0325" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0326" unitref="USD" xs:nil="true"></ix:nonfraction>
  <ix:nonfraction id="xdx2ixbrl0560" unitref="USD" xs:nil="true"></ix:nonfraction>
  </ix:hidden>
 <ix:references>
  <link:schemaref xlink:href="hltt-20211231.xsd" xlink:type="simple">
  </link:schemaref></ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">hltt:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">hltt:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">hltt:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">hltt:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">hltt:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-112020-11-12_custom_ExchangeAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">hltt:ExchangeAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-11-11</xbrli:startdate>
        <xbrli:enddate>2020-11-12</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-112020-11-12_custom_MediScanIncMember_custom_SeriesAPreferredsStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">hltt:MediScanIncMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:SeriesAPreferredsStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-11-11</xbrli:startdate>
        <xbrli:enddate>2020-11-12</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-07_custom_HealthtechSolutionsMember_custom_SeriesCPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">hltt:HealthtechSolutionsMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:SeriesCPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-01</xbrli:startdate>
        <xbrli:enddate>2021-05-07</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_VarianBiopharmaceuticalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">hltt:VarianBiopharmaceuticalIncMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-07_custom_VarianBiopharmaceuticalIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">hltt:VarianBiopharmaceuticalIncMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-01</xbrli:startdate>
        <xbrli:enddate>2021-05-07</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-09_custom_HealthcareSolutionIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">hltt:HealthcareSolutionIncMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-09</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-07</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-012020-12-31_custom_DenisKleinfeldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">hltt:DenisKleinfeldMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-08-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DenisKleinfeldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">hltt:DenisKleinfeldMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_RobertBrantllMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">hltt:RobertBrantllMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_StormFundingLLCMember_custom_MayTwoThousandTwentyMember_custom_DavidRubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">hltt:StormFundingLLCMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">hltt:MayTwoThousandTwentyMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">hltt:DavidRubinMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MayTwoThousandTwentyMember_custom_MrRubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardDateAxis">hltt:MayTwoThousandTwentyMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">hltt:MrRubinMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_EProdigyFinancialLLCMember_custom_MrRubinMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">hltt:EProdigyFinancialLLCMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">hltt:MrRubinMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_DenisKleinfeldMember_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">hltt:DenisKleinfeldMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">hltt:AdvisoryAgreementMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-10</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-11-012021-11-10_custom_GeneralCounselMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">hltt:GeneralCounselMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-11-01</xbrli:startdate>
        <xbrli:enddate>2021-11-10</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-11-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-11-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_CommonStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">hltt:CommonStockOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_SeriesAPreferredStockOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:SeriesAPreferredStockOneMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_UndesignatedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:UndesignatedPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_MediScansFounderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hltt:MediScansFounderMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2018-01-01</xbrli:startdate>
        <xbrli:enddate>2018-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-10-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-10-01</xbrli:startdate>
        <xbrli:enddate>2021-10-06</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-10-012021-10-06_custom_SeriesAPreferredStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:SeriesAPreferredStocksMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-10-01</xbrli:startdate>
        <xbrli:enddate>2021-10-06</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-01</xbrli:startdate>
        <xbrli:enddate>2021-05-06</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012020-12-31_custom_MediScansFounderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hltt:MediScansFounderMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2018-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_MediScansFounderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hltt:MediScansFounderMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-05-01</xbrli:startdate>
        <xbrli:enddate>2020-05-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-04-01</xbrli:startdate>
        <xbrli:enddate>2021-05-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-012020-09-30_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-08-01</xbrli:startdate>
        <xbrli:enddate>2020-09-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-012020-11-30_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-11-01</xbrli:startdate>
        <xbrli:enddate>2020-11-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-03-302021-03-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:CommonSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-03-30</xbrli:startdate>
        <xbrli:enddate>2021-03-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:CommonSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:CommonSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">hltt:CommonSharesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2020-01-01</xbrli:startdate>
        <xbrli:enddate>2020-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-012021-05-06_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-05-01</xbrli:startdate>
        <xbrli:enddate>2021-05-06</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-04-01</xbrli:startdate>
        <xbrli:enddate>2021-06-30</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_custom_MediScanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001307624</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:LegalEntityAxis">hltt:MediScanMember</xbrldi:explicitmember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startdate>2021-01-01</xbrli:startdate>
        <xbrli:enddate>2021-12-31</xbrli:enddate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitnumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitnumerator>
        <xbrli:unitdenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitdenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">SECURITIES AND EXCHANGE COMMISSION</p>

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0; text-indent: 0.5in">Washington,
D.C. 20549<br>
_____________________</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">FORM <span id="xdx_900_edei--DocumentType_c20210101__20211231_zoOoxbWFj5ak"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:DocumentType" inside-table="false" id="fact-identifier-4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 10pt">(Mark One)</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 48px; text-align: center"><span style="font-size: 11pt"><span id="xdx_902_edei--DocumentAnnualReport_c20210101__20211231_zPKCV9YOQhr8" style="display: none"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:DocumentAnnualReport" inside-table="true" id="fact-identifier-5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></span>[√]</td>
    <td><span style="font-size: 11pt">ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 11pt">FOR THE FISCAL YEAR ENDED <span id="xdx_90D_edei--DocumentPeriodEndDate_c20210101__20211231_zhOYznkJMnyi"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" inside-table="true" id="fact-identifier-6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span id="xdx_900_edei--CurrentFiscalYearEndDate_c20210101__20211231_zVakPK9C42o9"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" inside-table="true" id="fact-identifier-7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">DECEMBER 31</ix:nonnumeric></span></span>, 2021</ix:nonnumeric></span></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 11pt"><span id="xdx_90F_edei--DocumentTransitionReport_c20210101__20211231_zLVuLSSJuZ1g" style="display: none"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" inside-table="true" id="fact-identifier-8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></span>[&nbsp;&nbsp;&nbsp;]</td>
    <td><span style="font-size: 11pt">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 11pt">For the transition period from _____ to _____</span></td></tr>
  </tbody></table>
<p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">Commission File No. <span id="xdx_902_edei--EntityFileNumber_c20210101__20211231" title="Entity File Number"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityFileNumber" inside-table="false" id="fact-identifier-9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0-51012</ix:nonnumeric></span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b><span id="xdx_90D_edei--EntityRegistrantName_c20210101__20211231_zgg24lNnM75j"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityRegistrantName" inside-table="true" id="fact-identifier-10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">HEALTHTECH SOLUTIONS, INC./UT</ix:nonnumeric></span></span></b></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">(Exact Name of Registrant as Specified in its Charter)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt"><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zm5tHj3nOyfk"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" inside-table="true" id="fact-identifier-11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Utah</ix:nonnumeric></span></span></span></td>
    <td colspan="2" style="border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt"><span id="xdx_90D_edei--EntityTaxIdentificationNumber_c20210101__20211231" title="Entity Tax Identification Number"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityTaxIdentificationNumber" inside-table="true" id="fact-identifier-12" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84-2528660</ix:nonnumeric></span></span></span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">(State or Other Jurisdiction of incorporation or organization)</span></td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">(I.R.S. Employer I.D. No.)</span></td></tr>
  <tr style="vertical-align: top">
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="4" style="padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="border-bottom: black 0.5pt solid; font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_900_edei--EntityAddressAddressLine1_c20210101__20211231_za0s69Fq2FQ7"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressAddressLine1" inside-table="true" id="fact-identifier-13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">181 Dante Avenue</ix:nonnumeric></span></span>,
    <span id="xdx_903_edei--EntityAddressCityOrTown_c20210101__20211231_zbpwgvkpFJ01"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressCityOrTown" inside-table="true" id="fact-identifier-14" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Tuckahoe</ix:nonnumeric></span></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20210101__20211231_zpdBaap5JO7j"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressStateOrProvince" inside-table="true" id="fact-identifier-15" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">NY</ix:nonnumeric></span></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20210101__20211231_zWEo2cS75693"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityAddressPostalZipCode" inside-table="true" id="fact-identifier-16" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10707</ix:nonnumeric></span></span></p></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">(Address of Principal Executive Offices)</span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">Issuer’s Telephone Number: <span id="xdx_904_edei--CityAreaCode_c20210101__20211231" title="City Area Code"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:CityAreaCode" inside-table="true" id="fact-identifier-17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">844</ix:nonnumeric></span></span>-<span id="xdx_908_edei--LocalPhoneNumber_c20210101__20211231" title="Local Phone Number"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:LocalPhoneNumber" inside-table="true" id="fact-identifier-18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">926-3399</ix:nonnumeric></span></span></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="width: 26%">&nbsp;</td>
    <td style="width: 25%">&nbsp;</td>
    <td style="width: 31%">&nbsp;</td>
    <td style="width: 18%">&nbsp;</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">	Securities Registered Pursuant to Section 12(b) of the Act:
	</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 35%; text-align: center">Title of Each Class</td>
    <td style="border-bottom: black 1pt solid; width: 15%; text-align: center">Trading Symbol</td>
    <td style="border-bottom: black 1pt solid; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center">Name of Each Exchange on Which Registered</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 10pt; text-align: center">None</td>
    <td style="padding-bottom: 10pt; text-align: center">None</td>
    <td colspan="2" style="padding-bottom: 10pt; text-align: center">Not Applicable</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">Securities Registered Pursuant to Section 12(g)
of the Act:</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><span id="xdx_904_edei--Security12gTitle_c20210101__20211231" title="Title of 12(g) Security"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:Security12gTitle" inside-table="false" id="fact-identifier-19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Stock, $.001 par value per share</ix:nonnumeric></span></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 406 of the Securities Act. Yes __ <span id="xdx_908_edei--EntityWellKnownSeasonedIssuer_c20210101__20211231" title="Entity Well-known Seasoned Issuer"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityWellKnownSeasonedIssuer" inside-table="false" id="fact-identifier-20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="text-decoration: underline">√_</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the Act. Yes __ <span id="xdx_903_edei--EntityVoluntaryFilers_c20210101__20211231" title="Entity Voluntary Filers"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityVoluntaryFilers" inside-table="false" id="fact-identifier-21" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="text-decoration: underline">√_</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. <span id="xdx_90E_edei--EntityCurrentReportingStatus_c20210101__20211231" title="Entity Current Reporting Status"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityCurrentReportingStatus" inside-table="false" id="fact-identifier-22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span> <span style="text-decoration: underline">√_</span> No __</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit such files.) <span id="xdx_90D_edei--EntityInteractiveDataCurrent_c20210101__20211231" title="Entity Interactive Data Current"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:EntityInteractiveDataCurrent" inside-table="false" id="fact-identifier-23" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span> <span style="text-decoration: underline">√_</span> No___</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Indicate by check mark if disclosure of delinquent filers pursuant
to Item 405 of Regulation S-K (§ 229.405) is not contained herein, and will not be contained, to the best of registrant's knowledge,
in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
Yes <span style="text-decoration: underline">_</span> No <span style="text-decoration: underline">√</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company. or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check One)</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">Large accelerate filer__Accelerated filer__<span id="xdx_908_edei--EntityFilerCategory_c20210101__20211231" title="Entity Filer Category"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" inside-table="false" id="fact-identifier-24" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span>_Smaller reporting company <span id="xdx_90C_edei--EntitySmallBusiness_c20210101__20211231" title="Entity Small Business" style="display: none"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness" inside-table="false" id="fact-identifier-25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span>[√] Emerging growth company <span id="xdx_902_edei--EntityEmergingGrowthCompany_c20210101__20211231_zxLsLEbdmUB6" style="display: none"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" inside-table="false" id="fact-identifier-26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span>__</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. [ ]</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).<br>
Yes __ <span id="xdx_904_edei--EntityShellCompany_c20210101__20211231" title="Entity Shell Company"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany" inside-table="false" id="fact-identifier-27" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span> <span style="text-decoration: underline">√</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">As of June 30, 2021 (the last business day of the most recently
completed second fiscal quarter) the aggregate market value of the common stock held by non-affiliates was $<span id="xdx_90A_edei--EntityPublicFloat_iI_pp0p0_c20210630_zK7N8mCzYxuc" title="Entity Public Float"><span><ix:nonfraction name="dei:EntityPublicFloat" contextref="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,953,193</ix:nonfraction></span></span>.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">As of April 14, 2022, there were <span id="xdx_903_edei--EntityCommonStockSharesOutstanding_iI_c20220414_z59qWnekEPNh" title="Entity Common Stock, Shares Outstanding"><span><ix:nonfraction name="dei:EntityCommonStockSharesOutstanding" contextref="AsOf2022-04-14" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,965,933</ix:nonfraction></span></span> shares of common stock
outstanding.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE:</b>
None</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORWARD-LOOKING STATEMENTS: NO ASSURANCES INTENDED</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0 9pt; text-indent: 0.5in">This Annual Report contains certain forward-looking
statements regarding Healthtech Solutions, Inc., its business and financial prospects. All statements that address events or developments
that we expect or anticipate will occur in the future are forward-looking statements. These statements represent Management’s best
estimate of what will happen. Nevertheless, there are numerous risks and uncertainties that could cause our actual results to differ dramatically
from the results suggested in this Report, including the contingencies described in this Report under Item 1A titled "Risk Factors".</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Because these and other risks may cause the
Company’s actual results to differ from those anticipated by Management, the reader should not place undue reliance on any forward-looking
statements that appear in this Report.</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">PART 1</span></b></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Item 1. Business</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>Overview</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Healthtech Solution Inc. (“Healthtech”
or the “Company”) is a life sciences company dedicated to building impactful solutions for people and the healthcare system
through an innovative portfolio model approach that fosters the maturation of subsidiary companies with products ranging in development
from early stage through commercial growth. We are agnostic to the clinical solution because we believe that to accomplish our mission
of improving lives that all options should be on the table, including therapeutics, devices, diagnostics, and digital technology. In fact,
we hypothesize that some of the most promising breakthroughs will occur at the interface of these traditional silos, which has already
begun to occur. Examples include drug delivery innovation combining advanced therapeutics and devices, human-machine interfaces combining
medical devices with digital technology, and companion diagnostics that determine the ideal patient candidate for new therapeutics. Healthcare,
illness, and injury are multifactorial, and we believe the solutions often need to be multi-pronged to succeed.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our business model begins with the identification
of target subsidiary companies through our broad network of relationships in academia and industry that continually provide access to
new opportunities. Upon thorough due diligence and confirmation of a mutual fit for both Healthtech and the potential portfolio company,
we bring the company and/or its technology into a Healthtech subsidiary where we will provide funding and operational support to achieve
value enhancing milestones and accelerate the organization’s mission. Upon achieving the targeted value inflection, we will work
closely with our subsidiaries to prepare for their independent launch and spin-out. At spin-out, equity is returned in a hybrid structure
that results in immediate disbursement of spin-out equity to Healthtech’s shareholders as well as a portion returned to the parent
company for re-investment in new opportunities. Through this approach, Healthtech shareholders continually gain exposure to early-stage
life science technologies that are approaching the steepest portion of their value creation curve through an investment structure that
is devoid of the “carry” typically imposed by a traditional private equity/venture capital fund. Furthermore, we roll up
our sleeves and provide significant operational and leadership support to our portfolio companies, increasing their chances of success
and decreasing their capital requirements. We believe this multiplies the impact of the funding provided to each subsidiary compared
to the traditional passive investing model – and so do our portfolio companies.</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Currently, there are three subsidiaries in
the Healthtech family: Healthtech Wound Care, Inc. (“HWC”), Medi-Scan Inc. (“MediScan”), and RevHeart Inc. (“RevHeart”).
We intend to complete further transactions that will build synergies across the organization, creating a diverse portfolio of assets
that still allows us to leverage skillsets and costs amongst our first partners.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt"><b>Our Portfolio Subsidiaries</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><b><i>Healthtech Wound Care, Inc.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In January 2022, Healthtech Wound Care, Inc.
(“HWC”) acquired the assets of Predictive Biotech, Inc. (“PBI”) that were related to PBI’s business of developing
novel wound care products for acute and chronic wounds. HWC’s plan is to use those assets as the foundation for HWC’s program
of identifying and developing a pipeline of human cell and tissue product (HCT/Ps) candidates that we believe have novel mechanisms of
action and immediate clinical potential in accordance with applicable federal regulations.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Prior to the January 2022 asset sale, PBI had
developed AmnioBind, a placental membrane allograft designed to act as a covering or barrier for the protection of burns and non-healing
wounds such as diabetic foot ulcers. The product is provided in multiple sizes to be applied directly to clean, debrided wounds where
bacterial burden and offloading have been addressed. The base material for AmnioBind is collected from live, healthy, births from appropriately
screened donors. The collected placental tissue is washed, dehydrated, cut, packaged, <span>and sterilized
</span>for commercial distribution. AmnioBind is processed in compliance with US CFR Title 21 Part 1271 and Section 361 of the Public
Health Service Act and regulated as a human cell and tissue product. <span style="letter-spacing: -0.4pt">This regulatory status was confirmed
in writing on August 23, 2021, by the Tissue Reference Group of the Food and Drug Administration. PBI applied for and was granted a Q-code
(Q-4225, per square cm) by the Centers for Medicare and Medicaid, effective 4/1/2022. A provisional patent covering the manufacturing
steps and clinical uses for AmnioBind was filed in September, 2021. The patent filing process is expected to be completed in Q2, 2022.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><span>As part
of the January asset sale, PBI assigned to HWC the right to market AmnioBind for HWC’s own account as well as control over PBI’s
own marketing of AmnioBind and other wound care products that may be developed. PBI also assigned to HWC control over the future development
of wound care products, whether developed by HWC or PBI.</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-indent: 0.5in">Increasing numbers of patients with
chronic and acute wounds are resulting in a growing demand for wound care products globally. An estimated 2.5% of the U.S.
population suffers from chronic wounds, including diabetic foot ulcers, pressure ulcers, and others. As a result, the adoption rate
of wound care products, including traditional therapies, bioactive therapies (including skin substitutes and growth factors) and
others, is increasing. Technological advancements in bioactive therapies, such as reduction in overall duration and cost of
treatment, have further attracted the patient population to these products. The global wound care market is projected to grow from
USD 18.51 billion in 2022 to USD 28.23 billion by 2029, exhibiting a CAGR of 6.2% during the forecast period.<br>
</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Predictive Biotech intends to
further elucidate the efficacy mechanism of action of AmnioBind in a clinical study in which AmnioBind (in addition to standard of care)
is compared to a commercially available product and standard of care alone. AmnioBind, along with standard of care, is expected to significantly
reduce treatment times of patients when compared to standard of care alone.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><i><span style="text-decoration: underline">The Wound Care Market and
Placental Tissue </span></i></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Skin conditions, which include but are not limited
to wounds, can be devastating to patients. There are an estimated 500,000 burns treated in the United States each year, and globally this
statistic increases to 11 million injuries per year. The overall mortality rate for burn injury has been estimated to have been 4.9% between
1998-2007 and medical costs for burn treatments approach $2 billion per year. In addition, chronic wounds constitute a large patient base
and healing rates remain below 50%. These non-healing chronic wounds are estimated to affect 7 million people in the United States. Patients
who suffer from these skin conditions can benefit from rapid treatments that result in at least partial closure and protection of the
wounds.</p>

<p style="font: 12pt/98% Times New Roman, Times, Serif; margin: 0.05pt 30.75pt 0 0">&nbsp;</p>

<p style="font: 12pt/98% Times New Roman, Times, Serif; margin: 0.05pt 30.75pt 0 0; text-indent: 0.5in">Diabetic foot ulcers (DFUs) are
a major health complication that will affect up to 15% of individuals with diabetes mellitus over their lifetime. The treatment of DFUs
is an extremely challenging scenario, as these ulcers may be recalcitrant to SOC treatments, thus increasing the risk of infection and
sequelae such as amputations. It is estimated that approximately 15% of all DFUs will result in a lower extremity amputation and develop
concomitant medical complications that are associated with increased mortality rates.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 30.75pt 0 0; text-indent: 0.5in">DFUs not only have a detrimental effect
on a patient’s quality of life, but also pose a significant burden on healthcare facilities and the public and/or private payers
who support these facilities. Waycaster et al. noted a recent economic evaluation of Medicare beneficiaries which concluded that the United
States spent $32B USD in 2014 on 8.2 million patients This equates to approximately $4,000 USD per patient.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 13.1pt 30.65pt 0 0; text-indent: 0.5in">Human amniotic membrane has been used
in the treatment of wounds since the early 20th century. Numerous potential applications of this tissue have been investigated since then.
<span style="letter-spacing: 0.05pt">S</span>tudies have demonstrated that amniotic membranes have anti-inflammatory effects, are antimicrobial,
demonstrate anti-scarring, maintain an anti-adhesive activity, are non-immunogenic with low antigenicity, have analgesic properties, and
promote re- epithelialization. One noted application is for use in patients with DFUs. A recent systematic review and meta-analysis by
Laurent et al. concluded that “[h]uman amnion/chorion membrane + standard of care treatment heals DFUs significantly faster than
standard of care alone.”</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline"></span></i></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Facilities for Wound Care Operations</span></i></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">PBI’s laboratory facility is register with
the U.S. Food and Drug Administration as a Human Cell and Tissue Establishment, FDA Establishment Identifier (FEI): 3012707547. The
facility includes two (2) ISO Class 7 cleanrooms containing twelve (12) ISO Class 5 Biological Safety Cabinets. The equipment and
facilities are inspected and validated semiannually by independent contractors to ensure that all are functioning correctly.
PBI’s facility conforms to current Good Tissue Practices (21 CFR 1271.150), current Good Manufacturing Practices and is ISO
13485 certified. These facilities will be used in manufacturing AmnioBind and other products for commercial use and for experimental
use in Investigational New Drug Applications. Since the sale of assets in January 2022, the lab facility has operated under the
direction of HWC.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><b><i>MediScan, Inc.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">MediScan is a company developing advanced ultrasound
imaging and artificial intelligence (“AI”) based image analysis software. Within the past few years, medical professionals
have realized the wide-spread versatility of handheld ultrasound devices. Point-of-care ultrasound (“POCUS”) and handheld
systems now represent a rapidly growing portion of sales of ultrasound technology in the United States and worldwide. Ultrasound devices
with the AI-based software applications MediScan is developing have the potential to enable healthcare professionals to more efficiently
triage and prioritize workflows due to enhanced visualization and/or computer-assisted analysis of suspected findings.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">MediScan is developing its AI-based software
for analysis of ultrasound images of the chest (primarily lung) and musculoskeletal (“MSK”) system. The software is being
trained with validated ultrasound images using AI algorithms. Once sufficiently trained for each targeted disease or injury pattern, we
expect that the AI-based software will be capable of analyzing images and studies for suspected diseases or injuries to assist with triage
and prioritization in point-of-care settings. These systems will not alter the images and will not be intended to be used as a diagnostic
device, at least initially. As training of each system is completed, resulting in proof-of-concept data, MediScan will define and design
the necessary validation studies to pursue regulatory clearance for each application, while continuing to enhance the capabilities within
each organ or tissue system. In addition to the lead development programs focused on chest and MSK ultrasound software analysis, we are
evaluating other organ systems, disease states, or tissues that could benefit from a similar point-of-care (“POC”) solution
based on unmet needs and workflow challenges with current solutions. In parallel, we are developing a cloud-based software system capable
of converting two-dimensional analog grayscale ultrasound images into a digital three-dimensional high-definition color format with the
goal of expanding the visual image available to the healthcare provider (“HCP”).</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in">MediScan has filed two
provisional patent applications with the U.S. Patent and Trademark Office listed below, and through its ongoing research efforts, MediScan
expects to develop additional technology and application methods of strategic value to the Company, for which it may seek patent protection.</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tbody><tr style="vertical-align: top">
    <td>&nbsp;</td>
<td style="width: 0.25in"></td><td style="text-align: center; width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support; and</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
<td></td><td style="text-align: center"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">System, Method, and Apparatus for Monitoring Cardiac Tissue Damage.</td></tr></tbody></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"></p>


<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">We
intend to market our imaging technology through the Software as a Service ("SaaS") model. SaaS is a business model where the
software system is held in the cloud and accessed by a local computer, tablet or smartphone via the internet. The healthcare industry
is adopting the SaaS model for clinical information systems (such as PACS, EHR, telehealth applications, treatment planning software)
and nonclinical information systems (such as billing, revenue cycle management, and supply chain management).</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Understanding that not every healthcare system
and practice has adopted widespread use of the SaaS model, we are further attracted to POCUS solutions, which have less barriers to entry
to facilitate for SaaS models compared to the traditional imaging solutions that are contained within large hospital systems and imaging
centers, that may be reluctant to on-board numerous single algorithms that are now gaining FDA clearance. The Canadian Association of
Radiologists highlighted this sentiment stating, “Ultimately, the driver of clinical adoption may reside in the implementation and
availability of AI applications integrated into the PACS system at the reading station.” Within the last three years since that
white paper was written, the field of AI in medicine has accelerated, now with numerous AI-based software assistants cleared by the FDA,
and new solutions to large scale integration blossoming in the form of medical AI algorithm marketplaces. AI marketplaces and larger multimodal
AI infrastructure have the potential to accelerate the adoption of AI in medicine by creating a model that mirrors “app stores”
- algorithms that provide the greatest value can compete.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We believe the market opportunity for AI-based
medical image analysis is large, that it will grow rapidly over the next ten years, and that regulatory and industry solutions are now
developed to the point of making the commercialization and adoption of medical AI-based software feasible. In regard to the handheld POCUS
probes and devices alone, the global portable ultrasound market size is projected to reach $3.9 billion in 2026, according to Fortune
Business Insights. The market stood at $1.8 billion in sales in 2019 with a projected CAGR of 13.6% from 2020 to 2026. North America accounted
for $733 million in sales in 2019 and is expected to remain the market leader.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The global ultrasound image analysis software
market, separate from the POCUS hardware market described above, is projected to reach between $2.9 and $4.5 billion by 2025. Both markets
are expected to synergistically drive each other, with increasing adoption of POCUS hardware due to AI image analysis reducing expertise
to perform POCUS. Furthermore, these projections may already be underestimating the adoption of POCUS devices due to the acceleration
of use throughout the COVID-19 pandemic, where POC solutions that limited patient movement and provided information allowing for rapid
triage became necessities.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Within the last three years, numerous AI-based
software assistants have been cleared by the United States Food and Drug Administration (“FDA”). New solutions to large scale
integration of these narrowly focused algorithms are becoming available as “medical AI algorithm marketplaces”. These marketplaces
may be able to aggregate the growing number of algorithms, and seamlessly integrate them into radiologists’ or healthcare systems’
workflows. The currently available medical AI algorithm marketplaces and more advanced infrastructure solutions being designed by large
companies could lower the barriers to entry for new products with highly focused niche applications.</p>


<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><b><i>RevHeart, Inc.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">RevHeart is a discovery stage company focused
on novel approaches to correct cardiac rhythm abnormalities using electromagnetic waveforms in an innovative approach called entrainment,
building from advances gained in other disease states. Entrainment, which is currently used in tachycardia (rapid heartbeat), works by
linking the patient’s abnormal heart rhythm together with a normal heart rhythm, and gently encouraging the abnormal rhythm to revert
to a more normal rhythm. As part of these efforts, RevHeart is developing software technology that compares a healthy heart rhythm electronic
signal with a damaged heart’s signal, and subsequently derives an electronic signal representing the potentially curative waveform.
Then, through a monitored feed-back mechanism, the curative electronic signal would be introduced to the patient to achieve a reversion
to the healthy heart rhythm. RevHeart plans to develop the software and prototype of the device capable of testing the hypothesis that
entrainment can convert abnormal electrocardiogram (“ECG”) waveforms into normal ECG waveforms through iterative corrective
signals.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">RevHeart
has filed a provisional patent application with the U.S. Patent and Trademark Office </span>listed below, and through its ongoing research
efforts, RevHeart expects to develop additional technology and application methods of strategic value to the Company, for which it may
seek patent protection.</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 12pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td>
    <td>&nbsp;</td><td style="text-align: center; width: 0.25in"><span style="font-family: Symbol">·</span></td><td style="text-align: justify">System, Method and Apparatus for Stimulating Cardiac Muscle Injury Recovery.</td></tr></tbody></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">All cardiac rhythm abnormalities could potentially
benefit from the RevHeart device and entrainment, such as atrial fibrillation (“AFib”) and conduction system diseases. AFib
is projected to affect between 6 and 12 million people in the United States by 2050. According to Markets and Markets, the cardiac monitoring
and rhythm management devices market is projected to reach $26. billion worldwide by 2025 with a projected CAGR of 4.0% from 2020 to 2025,
with the United States occupying the largest share of the market.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>Our Portfolio Investment</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As noted above, our business plan contemplates that
we will acquire Portfolio Subsidiaries in their early stages of development, nurture them until they are market-ready, then transfer our
control via spin-out or otherwise, while retaining a minority interest in the newly-independent company as a Portfolio Investment. At
present, we hold one Portfolio Investment, a 5.5% interest in the equity of Varian Biopharmaceuticals, Inc. (“Varian”),</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Varian Biopharmaceuticals, Inc.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Varian is an emerging biopharmaceutical company
focused on the development of novel, targeted oncology therapies with transformational potential for cancer patients. Varian’s strategy
is to identify, license and develop a pipeline of therapeutic candidates that they believe have novel mechanisms of action and transformative
clinical potential, and then to bring the requisite scientific and clinical resources together to move them forward in the promise of
safer and more effective cancer treatments.</p>


<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Varian
is developing VAR-101/102, a high-potency, specific, atypical Protein Kinase C iota (“aPKCi”) inhibitor in two formulations.
Recently, numerous scientific publications have identified aPKCi as an oncogene, whose presence and activation has been implicated in
the development and growth of multiple forms of human cancer including basal cell carcinoma (“BCC”), cutaneous T-cell lymphoma
(“CTCL”), pancreatic, non-small cell lung cancel (“NSCLC”), acute myeloid leukemia (“AML”) and others.
The active pharmaceutical ingredient in VAR-101/102, an aPKCi inhibitor, has demonstrated dose dependent anti-tumor activity in murine
and human BCC cell lines, as well as other cancer models. Varian intends to develop VAR-101 in a topical formulation for BCC which has
the potential to offer optimal clinical utility in BCC as a surgical neoadjuvant or adjuvant therapy. VAR-102, an oral formulation of
the active aPKCi inhibitor, lends itself to broader applications in multiple tumor types. Varian believes that VAR-101 and VAR-102, if
approved, could represent significant medical and commercial opportunities. Varian has agreements in place with contract manufacturers
and research organizations, and consulting groups, for API synthesis, formulation and non-clinical studies to progress the development
of VAR-101 and VAR-102 in IND enabling activities.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In May 2021 Healthtech Solutions acquired all of the
equity in Varian. Between May 2021 and November 2021, Healthtech Solutions contributed approximately $900,000 to fund the ongoing operations
of Varian, while Healthtech management and the Varian management team jointly pursued the financing that Varian requires to become market-ready.
In November 2021, the parties agreed to sever the relationship: Healthtech Solutions returned 94.5% of the equity in Varian to its original
owners. Healthtech Solutions now holds the remaining 5.5% equity interest in Varian as its initial Portfolio Investment.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white"><b>Regulatory Requirements</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">HWC’s AmnioBind
product has received all necessary regulatory clearance to be marketed for wound care indications. MediScan’s imaging APP, therefore,
is the only product in our portfolio at this time for which regulatory approval will be required. The following discussion, therefore,
focuses on the regulations that will be applicable to the imaging APP. As we expand our portfolio, however, other aspects of federal and
state regulation of products for medical application will become relevant.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white"><b><i>FDA Medical Device
Regulation</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 2.55pt 0 10pt; text-indent: 0.5in">The U.S. Food and Drug Administration ("FDA")
has broad authority over the regulation of medical devices marketed for sale in the United States, as well as medical devices manufactured
in the United States and exported to international markets. Medical devices must be shown to be safe and effective for their intended
use, and data demonstrating safety and effectiveness that is provided to the FDA must be adequate to enable the agency to make regulatory
decisions related to marketing approval.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Under the U.S. Food, Drug, and Cosmetic Act
("FDCA"), the FDA classifies each medical device into one of three classes: Class I, Class II or Class III. Class I medical
devices are deemed to pose the lowest risk to the patient. We anticipate that MediScan’s imaging APP will be reviewed as a Class
I device since it consists of software and there are no patient-facing components (i.e. nothing touches the patient and there is no energy
transfer to the patient). In addition, our imaging APP is not completely novel, and there are legally marketed devices that can be used
as predicate devices. The safety and efficacy of our imaging APP can be assured through the use of general and special controls, and
the technology used is sufficiently similar that risks and benefits of the technology can be evaluated using prior knowledge.</p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">We anticipate that the FDA will require primarily
software-based testing, which will compare the accuracy and consistency of clinical interpretations using the product versus interpretations
using an alternative imaging modality, with limited requirements for clinical testing. It will be necessary to provide data related to
software validation and verification. From the perspective of FDA, software validation and verification are required under the Quality
System <span style="letter-spacing: -0.15pt">R</span>egulations. Validation determines if the product works as intended for the end user;
verification confirms that the software, as coded, functions properly. Software validation establishes, using objective evidence, that
the device specifications conform with user needs and intended uses, and is demonstrated by identifying user needs and testing against
those needs to ensure that the product requirements and software specifications result in a software product that meets those needs. Validation
testing is typically conducted through use cases or clinical testing.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Verification testing confirms that the output
of the software matches inputs and confirms using objective evidence that the specified requirements have been fulfilled. Accurate and
detailed product requirements and design specifications are necessary to permit efficient verification testing. Testing should confirm
that the product both performs as intended, and in the way anticipated. Verification testing will also include verification of adequate
design for purposes of assuring the cybersecurity of the device.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 2.55pt 0 10pt; text-indent: 0.5in">Class I medical devices are subject to
the lowest degree of regulatory scrutiny and need only comply with the FDA’s General Controls. The General Controls include compliance
with the registration, listing, adverse event reporting requirements, and applicable portions of the Quality Systems Regulations, or QSR,
as well as the general misbranding and adulteration prohibitions. Unless specifically exempted in the regulations, General Controls require
most companies that intend to market a Class I medical device, such as our imaging APP, to gain clearance for marketing through the 510(k)
process.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">To obtain 510(k) clearance
for MediScan’s imaging APP, we will be required to submit a premarket notification demonstrating that the proposed medical device
is substantially equivalent in terms of safety and effectiveness to a previously cleared medical device used for the same indications.
Typically, data must be submitted to the FDA demonstrating similar technology and clinical and non- clinical performance, electromagnetic
compatibility, software validation, and when appropriate, biocompatibility characteristics. FDA’s 510(k) clearance pathway usually
takes from three to twelve months. On average the review time is approximately six months, but it can take significantly longer than twelve
months in some instances, as the FDA may require additional information, including clinical data, to make a determination regarding substantial
equivalence.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">We anticipate that
a separate 510(k) clearance will be required for each usage class for which we market our imaging APP - i.e. an application for lung scans,
an application for heart scans, an application for tendon scans, etc. However, each application will build on what was demonstrated in
prior applications, and so the time and expense required will reduce as we gain a body of approvals.</p>


<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">After a medical device
receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new
or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, require a PMA. The FDA requires
each manufacturer to determine whether the proposed change requires submission of a new 510(k) notice, or a premarket approval, but the
FDA can review any such decision and can disagree with a manufacturer’s determination. If the FDA disagrees with a manufacturer’s
determination, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or premarket
approval is obtained. Also, in these circumstances, the FDA may levy significant regulatory fines or penalties on the manufacturer.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Any of the devices that we are developing for
use in treatment of cardiomyopathy will be classified as Class III devices, which are those devices deemed by the FDA to pose the greatest
risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously
cleared medical device. Class III medical devices require a Pre-Market Approval ("PMA") before commercialization. This is the
most stringent regulatory review and requires substantial development of clinical data to demonstrate safety and effectiveness before
the FDA permits the device to be marketed. The Filing Fee payable to the FDA for a PMA is $365,657; the Small Business Fee is $91,414
(as compared to $12,432 and $3,108 for submission of a 510(k) application). In addition, to the extent that we are seeking approval for
a medical diagnostic or therapeutic product that would be classified as biologic or pharmaceutical product, FDA guidelines will require
that we partner with an FDA-approved biological or pharmaceutical company to perform the requisite studies. Such a partnering arrangement
may require that we license our technology to the partner for regulatory and marketing purposes.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">It is important to
note that, because the FDA’s determination is based on its evaluation of the data and regulatory decision-making regarding safety,
effectiveness and compliance with other legal and regulatory requirements, approval of a marketing application is not assured.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white"><b><i>Healthcare Regulation
in General</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">Our future business
operations and activities in the U.S. may be directly or indirectly subject to certain federal and state laws relating to the privacy
and security of health information, and state and federal laws designed to guard against healthcare fraud and abuse, including, but not
limited to, those described below.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 14px">&nbsp;</td>
    <td style="width: 29px; padding-bottom: 10pt">●&nbsp;&nbsp;</td>
    <td style="padding-bottom: 10pt">HIPAA, as amended by HITECH, established comprehensive requirements related to the privacy, security, and transmission of individually identifiable health information. It governs patient privacy practices of healthcare providers, health plans, and healthcare clearinghouses (or “covered entities”), as well as their respective business associates to the extent that they perform services for or on behalf of the covered entities that involve the use or disclosure of protected health information. HIPAA also mandates notification in the event of a breach and regulates standardization of data content, codes and formats used in healthcare transactions. Covered entities and business associates may be subject to significant civil and criminal penalties, as well as enforcement by state attorneys general, for violations of HIPAA or its implementing regulations.</td></tr>

<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-bottom: 10pt">●</td>
    <td style="padding-bottom: 10pt">HIPAA also imposes federal criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters.</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-bottom: 10pt">●</td>
    <td style="padding-bottom: 10pt">The federal Anti-Kickback Statute which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order, or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs.</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-bottom: 10pt">●</td>
    <td style="padding-bottom: 10pt">The federal Civil False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The “qui tam” or “whistleblower” provisions of the False Claims Act allow a private individual to bring actions on behalf of the federal government, alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery.</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-bottom: 10pt">●</td>
    <td style="padding-bottom: 10pt">The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transfer of remuneration to a Medicare or state health care program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies.</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="padding-bottom: 10pt">●</td>
    <td style="padding-bottom: 10pt">Analogous state fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to items or services reimbursed under Medicaid, other state programs, or, in some states, private third-party payors. In addition, many U.S. states have enacted patient confidentiality laws that protect against the disclosure of confidential medical information, and many states have adopted or are considering adopting further legislation in this area, including privacy safeguards, security standards, and data security breach notification requirements. These state laws, which may be even more stringent than the HIPAA requirements, many of which differ from each other in significant ways and are often not preempted by the federal requirements.</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">These and other
regulations of the U.S. FDA and other regulatory agencies in and outside the U.S. impose extensive compliance and monitoring
obligations on our business. We will also be subject to periodic inspections for compliance with applicable quality system
regulations, which govern the methods used in, and the facilities and controls used for, the design, manufacture, packaging, and
servicing of finished medical devices intended for human use. In addition, the FDA and other regulatory bodies, both in and outside
the U.S. (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human
Services, the U.S. Department of Justice, and various state Attorneys General), will monitor the promotion and advertising of our
products. Any adverse regulatory action, depending on its magnitude, may limit our ability to effectively market and sell our
products, limit our ability to obtain future premarket approvals or result in a substantial modification to our business practices
and operations.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">We plan to gain access
for our products to the E.U. market. In the E.U., a single regulatory approval process exists, and conformity with the legal requirements
is represented by the CE Mark. To obtain a CE Mark, defined products must meet minimum standards of performance, safety, and quality (i.e.,
the essential requirements), and then, according to their classification, comply with one or more of a selection of conformity assessment
routes. The competent authorities of the E.U. countries separately regulate the clinical research for medical devices and the market surveillance
of products once they are placed on the market. A new Medical Device Regulation was published by the E.U. in 2017 which imposes significant
additional premarket and postmarket requirements (EU MDR). Implementation of the new requirements is scheduled to commence in May 2021.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">The global regulatory
environment is increasingly stringent and unpredictable. Several countries that did not have regulatory requirements for medical devices
have established such requirements in recent years, and other countries have expanded, or plan to expand, their existing regulations.
While harmonization of global regulations has been pursued, requirements continue to differ significantly among countries. We expect this
global regulatory environment will continue to evolve, which could impact the cost, the time needed to approve, and ultimately, our ability
to obtain approvals for our products.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Employees</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Healthtech Solutions, Inc. currently has no full-time
employees; neither do any of its subsidiaries. The President of Healthtech Solutions devotes substantially all of his business time and
attention to our operations and is the only consultant to do so. He is assisted by approximately 20 hourly consultants who work for Healthtech,
Healthtech Wound Care and MediScan on a part-time basis. In addition, the personnel of Predictive Biotech, Inc. who are involved in the
wound care business assigned to HWC provide services to that business under the direction of HWC.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>Item 1A. Risk Factors</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><i>Investing in our common stock involves risk.
You should carefully consider the risks described below together with all of the other information contained in this Report, including
the financial statements and the related notes, before deciding whether to purchase any shares of our common stock. If any of the following
risks is realized, our business, financial condition or operating results could materially suffer. In that event, the trading price of
our common stock could decline and you may lose all or part of your investment.</i></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><b>Risks Attendant to Our Business Plan</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>Our business plan will fail unless we are able to secure substantial
additional capital contributions.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt">Note 3 to our consolidated financial statements for the year
ended December 31, 2021 discloses that our financial condition raises substantial doubt as to the Company’s ability to
continue as a going concern. The risk of investing in a company whose financial statements carry a going concern opinion is that you
are likely to lose all of your investment if the company fails to continue as a going concern. In our case,&nbsp;successful
introduction of wound care products to the market will require an investment of several million dollars, as will <i>c</i>ompletion
of the development of our imaging system and securing government approval of its use in the U.S and the European Union. Development
of follow-on technologies into marketable products will then require substantial additional capital investment. We currently have
only modest cash resources and will require significant capital contributions in order to fully implement our business plan. If we
fail to adequately capitalize our business and are not able to convert our business into a going concern, investors in us will lose
their investment.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>Medical technology development involves a lengthy and expensive process,
and we may be unable to commercialize on a timely basis, or at all, any products we may develop.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Before commercial sales of any of our products, we must demonstrate
through lengthy, complex and expensive studies, preclinical studies and clinical trials that the applicable product candidate is effective
for use in each target indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient
population and for its intended use. Clinical testing is expensive and can take many years to complete, and its outcome is inherently
uncertain. Our clinical research may fail to demonstrate substantial evidence of the effectiveness of our technologies for their intended
uses, which would prevent, delay or limit the scope of commercialization.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">There can be no assurance that the products now in development or
that we may seek to develop in the future will achieve technological feasibility, obtain regulatory approval or gain market acceptance.
Few research and development projects result in commercial products, and success in early clinical trials often is not replicated in later
studies. At any point, we may abandon development of a product candidate or we may be required to expend considerable resources repeating
clinical trials, which would adversely impact the timing for generating revenues from those products. If a clinical validation study fails
to demonstrate the prospectively defined endpoints of the study, we might choose to abandon the development of the product or product
feature that was the subject of the clinical trial, which could harm our business.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>We intend to acquire or invest in other businesses or technologies
within the healthcare field. These investments may dilute our stockholders’ ownership, increase our debt and cause us to incur significant
expenses</i>.&nbsp;<i>If they prove to be unsuccessful, the investments could damage our operating results.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">As part of our business strategy, we intend to pursue
acquisitions of complementary businesses and assets. We also may pursue strategic alliances that leverage our technology and
industry experience to expand our product offerings or distribution. If we make acquisitions, we may not be able to integrate these
acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Integration of an
acquired company also may require management resources that otherwise would be available for ongoing development of our existing
business. Any future acquisitions by us also could result in significant write-offs or the incurrence of debt and contingent
liabilities, any of which could harm our operating results. To finance any acquisitions or investments, we may choose to issue
shares of our common stock as consideration, which could dilute the ownership of our stockholders.</p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Our business entails a significant risk of product liability
and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial
condition. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">Our business exposes us to significant product liability risks inherent
in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion
of our development programs. If we succeed in marketing products, such claims could result in an FDA, EMA or other regulatory authority
investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA,
EMA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action,
limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits
or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend
the related litigation, a diversion of management’s time and our resources and substantial monetary awards to trial participants
or patients. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable
to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an
adverse effect on our business and financial condition.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>The COVID-19 pandemic could adversely impact our business, including
our planned development, manufacturing and pre-clinical studies. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">The COVID-19 pandemic in the United States and in other countries could
cause significant disruptions that could severely impact our business, including:</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="text-align: center; width: 0.5in">•</td><td>delays or difficulties in pre-formulation, formulation and manufacturing activities;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="text-align: center; width: 0.5in">•</td><td>delays or difficulties in recruiting advisors and consultants;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="text-align: center; width: 0.5in">•</td><td>inability or unwillingness of personnel to travel to the outside vendor sites;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="text-align: center; width: 0.5in">•</td><td>delays or difficulties in data collection and analysis and other related activities;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="text-align: center; width: 0.5in">•</td><td>interruption of key manufacturing and formulation development, due to limitations on travel imposed or recommended by federal or state
governments, employers and others;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="text-align: center; width: 0.5in">•</td><td>limitations in employee and consultant/advisor resources that would otherwise be focused on the conduct of our research and development
activities, including because of sickness of employees or their families or mitigation measures such as lock-downs and social distancing;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="text-align: center; width: 0.5in">•</td><td>changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our research
is conducted, which may result in unexpected costs, delays, or to discontinue the clinical trials altogether;</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="text-align: center; width: 0.5in">•</td><td>delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations
in employee resources or forced furlough of government employees; and</td></tr></tbody></table>





<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top"><td style="text-align: center; width: 0.5in">•</td><td>adverse impacts on global economic conditions which could have an adverse effect on our business and financial condition, 	including
impairing our ability to raise additional capital when needed.</td></tr></tbody></table>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">Such disruptions could impede, delay, limit or prevent completion of our manufacturing and formulation development, and preclinical studies
or commencement of future clinical trials and ultimately lead to the delay or denial of regulatory approval of our product candidates,
which would seriously harm our operations and financial condition and increase our costs and expenses. Future or revised stay-at-home
orders could result in delays or otherwise negatively impact our development activities. The COVID-19 pandemic could also affect the
business of the FDA or other health authorities which could result in delays in meetings related to planned clinical trials and ultimately
of reviews and approvals of our product candidates. Moreover, to the extent the evolving effects of the COVID-19 pandemic adversely affect
our business and financial condition, they may also have the effect of heightening many of the other risks and uncertainties described
elsewhere in this “Risk Factors” section.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>Risks Attendant to Our
Intellectual Property</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>Our success depends on our ability to protect
our intellectual property and our proprietary technologies. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">Our commercial success depends in part on our
ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies and
their uses, as well as our ability to operate without infringing the proprietary rights of others. If we or our licensors are unable to
protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates,
our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United
States and abroad related to our product candidates, proprietary technologies and their uses that are important to our business. Our patent
applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents
issue from such applications, and then only to the extent the issued claims read on the technology. There can be no assurance that our
patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with
similar technology, nor can there be any assurance that the patents, if issued, will not be infringed, designed around, invalidated or
rendered unenforceable by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked
in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary
rights is uncertain. Only limited protection may be available and such protection may not adequately protect our rights or permit us to
gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property
rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>


<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>Our commercial success depends significantly
on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we
infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">Our commercial success depends in part on avoiding
infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities
may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third
parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale
or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial
amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical
industry, including patent infringement lawsuits, oppositions, reexaminations, <i>inter partes</i> review proceedings and post-grant review
proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications
exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims
to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>We may become involved in lawsuits or administrative
disputes to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.
</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">Competitors and other third parties may infringe,
misappropriate or otherwise violate our patents, trademarks, copyrights, trade secrets or other intellectual property. To counter infringement,
misappropriation or other violations, we may be required to file infringement, misappropriation or other violation claims, which can be
expensive and time-consuming and divert the time and attention of our management and business and scientific personnel. In addition, many
of our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions
than we can. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor’s or potential competitor’s
product or service. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection
with their products and services.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">Any claims we assert against perceived infringers
could provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their patents
or their other intellectual property, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In
patent litigation in the United States, counterclaims challenging the validity, enforceability or scope of asserted patents are commonplace.
Similarly, third parties may initiate legal proceedings against us seeking a declaration that certain of our intellectual property is
not infringed, invalid or unenforceable. The outcome of any such proceeding is generally unpredictable.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>


<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">In addition to our reliance on patent protection,
we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain
our competitive position. Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into confidentiality
agreements with third parties, and confidential information and inventions agreements with employees, consultants, licensors and advisors,
we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements
and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.
Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Monitoring
unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary information
will be effective. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect
trade secrets.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">Moreover, third parties may still obtain this
information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology
or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of
this information may be greatly reduced and our competitive position would be harmed. If we or our licensors do not apply for patent protection
prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential
information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><b>Risks Attendant to Our Specific Products</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><b><span style="text-decoration: underline">Wound Care</span></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>Our wound care products are dependent on the availability of tissue
from human donors, and any disruption in supply could adversely affect our business.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">The success of our wound care products depends upon, among other factors,
the availability of tissue from human donors.&nbsp;Any failure to obtain tissue from our sources will interfere with our ability to effectively
meet demand for our products incorporating human tissue. The processing of human tissue into our products is very labor-intensive and
it is therefore difficult to maintain a steady supply stream. The availability of donated tissue could also be adversely impacted by regulatory
changes, public opinion of the donor process as well as our own reputation in the industry.&nbsp;The challenges we may face in obtaining
adequate supplies of human tissue involve several risks, including limited control over availability, quality, and delivery schedules.
In addition, any interruption in the supply of any human tissue component could materially harm our ability to manufacture our products
until a new source of supply, if any, could be found. We may be unable to find a sufficient alternative supply channel in a reasonable
time period or on commercially reasonable terms, if at all, which would&nbsp;have a material adverse effect on our business, results of
operations and financial condition.</p>


<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>The wound care products we intend to manufacture and process are
derived from human tissue and, therefore, have the potential for disease transmission.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">The utilization of human tissue creates the potential for transmission
of communicable disease, including, but not limited to, human immunodeficiency virus ("HIV"), viral hepatitis, syphilis and
other viral, fungal, or bacterial pathogens.&nbsp;&nbsp;We are required to comply with federal and state regulations intended to prevent
communicable disease transmission. Although we maintain strict quality controls over the procurement and processing of our tissue including
sterility testing by independent labs, there is no assurance that these quality controls will be adequate.&nbsp;&nbsp;In addition, negative
publicity concerning disease transmission from other companies' improperly processed donated tissue could have a negative impact on the
demand for our products.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>We will rely on a single laboratory facility to process our wound
care products.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">We will rely on a single laboratory facility in Salt Lake City, Utah that
we lease and operate to process our wound care products. This facility and certain pieces of laboratory equipment would be difficult to
replace and may require significant replacement lead-time. This facility could be affected by natural disasters such as earthquakes, floods,
and fires. In the event the facility or the equipment located in the facility are affected by man-made or natural disasters, we would
be unable to continue our wound care business and meet customer demands for a significant period of time. Any interruption in our wound
care business would result in a loss of goodwill, including damage to our reputation.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">Imaging APP</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>The success of our imaging system in securing a substantial
market will depend in part on our ability to maintain its compatibility with software systems used in the more popular portable ultrasound
devices.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Our imaging system will be designed to work in congress with generally
available portable ultrasound devices. It will be crucial, therefore, that the software in our system be compatible with the software
in most of those devices to enable it to efficiently interface with the ultrasound devices in use throughout the medical industry. If
we fail to keep abreast of impending changes in prevailing software systems, we could find it difficult to market our APP.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>Government regulation of our use of individually identifiable
data may increase our costs and interfere with the efficient use of our imaging system.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Both state and federal regulations apply to our use of
customer information in general, and particularly to our access to patient medical information. Our efforts to comply with such
regulations will entail development or purchase of costly software systems, which will reduce funds available for product
development.&nbsp;<span style="letter-spacing: -0.15pt">Additionally,&nbsp;</span>the success of our operations depends upon the
secure transmission of confidential information over public networks. The intentional or negligent actions of employees, business
associates or third parties may undermine our security measures. As a result, unauthorized parties may obtain access to our data
systems and misappropriate confidential data. There can be no assurance that advances in computer capabilities, new discoveries in
the field of cryptography or other developments will prevent the compromise of our patient information. If any such compromise of
our security or the security of information residing in our systems were to occur, it could have a material adverse effect on our
reputation, operating results and financial condition.</p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><b><span style="text-decoration: underline">Cardiac Therapy</span></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>Our research and development efforts with regard to cardiac
muscle shredding and lung lesions may be hindered if we are not able to contract with third parties for access to exomes or nanoparticles
and other biologic materials.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">As part of our development of a pharmaceutical and electromagnetic solution
to restoring a healthy heart muscle to COVID patients affected by heart muscle shredding, we will need to secure access to exosomes or
nanoparticles and other biologic materials. The process of negotiating access to such samples is lengthy because it typically involves
numerous parties and approval levels to resolve complex issues such as usage rights, institutional review board (IRB) approval, privacy
rights, publication rights, intellectual property ownership and research parameters. If we are unable to negotiate access to exosomes
or nanoparticles for clinical trials on a timely basis or on commercially reasonable terms, or at all, or if other laboratories or our
competitors secure access to these samples before us, our ability to research, develop and commercialize future products will be limited
or delayed.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><b>Risks Attendant to Our
Reliance on Third Parties</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>We rely, and expect to rely in the future,
on third parties, including independent clinical investigators, CMOs and CROs, to conduct certain aspects of our manufacturing, preclinical
studies and planned clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable
regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product
candidates and our business could be substantially harmed. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">We have relied upon and plan to rely in the future
upon third parties, including independent clinical investigators and third-party CMOs and CROs, to conduct certain aspects of our manufacturing,
preclinical studies and planned clinical trials and to monitor and manage data for our ongoing preclinical and planned clinical programs.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">We rely or will rely on these parties for
execution of our preclinical studies and planned clinical trials, and may not control, or will only control certain aspects of,
their activities. Nevertheless, we are or will be responsible for ensuring that each of our studies and trials is conducted in
accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does
not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP
requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our
products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial
sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable
GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory
authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you
that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our
failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval
process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or
false claims laws and regulations or healthcare privacy and security laws.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>Formulation and manufacturing our product
candidates is complex and we may encounter difficulties in production. If we encounter such difficulties, our ability to provide supply
of our product candidates for preclinical studies and clinical trials or for commercial purposes could be delayed or stopped. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">The process of formulating and manufacturing our
product candidates is complex and highly regulated.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">We expect to rely on third parties for the formulation
and manufacture of our product candidates. These third-party manufacturers may incorporate their own proprietary processes into our product
candidate manufacturing processes. We will have limited control and oversight of a third party’s proprietary process, and a third
party may elect to modify its process without our consent or knowledge. These modifications could negatively impact our manufacturing,
including product loss or failure that requires additional manufacturing runs or a change in manufacturer, both of which could significantly
increase the cost of and significantly delay the manufacture of our product candidates.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">As our product candidates progress through preclinical
studies and clinical trials towards approval and commercialization, it is expected that various aspects of the manufacturing process will
be altered in an effort to optimize processes and results. Such changes may require amendments to be made to regulatory applications which
may further delay the timeframes under which modified manufacturing processes can be used for any of our product candidates and additional
bridging studies or trials may be required.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>If our third-party manufacturers use hazardous
and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">Our research and development activities may
involve the controlled use of potentially hazardous substances, including chemical and biological materials, by our third-party
manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United States governing the
use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our
manufacturers’ procedures for using, handling, storing and disposing of these materials comply with legally prescribed
standards, we cannot completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a
result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use
of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or
penalized with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from
medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future
environmental regulations may impair our research, development and production efforts, which could harm our business, prospects,
financial condition or results of operations.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>&nbsp;</i></b></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>We may be unable to adequately protect our
information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal
data, damage our reputation, and subject us to significant financial and legal exposure. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">We will rely on information technology systems
that we or our third-party vendors operate to process, transmit and store electronic information. In addition, the COVID-19 pandemic has
intensified our dependence on information technology systems as many of our critical business activities have been conducted remotely.
In connection with our discovery and development efforts, we may collect and use a variety of personal data, such as name, mailing address,
email addresses, phone number and clinical trial information. A successful cyberattack could result in the theft or destruction of intellectual
property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our
operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect.
Moreover, the prevalent use of mobile devices to access confidential information increases the risk of security breaches. Cyberattacks
could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment
of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and
availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption
of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss
and the disclosure of corporate strategic plans.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0.25in 0pt 0pt">In addition, the information technology systems of various
third parties on which we rely, including our CMOs, CROs and other contractors, consultants and legal and accounting firms, may sustain
damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes
and earthquakes), terrorism, war and telecommunication and electrical failures. We rely on our third-party providers to implement effective
security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to
maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant
disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling
such cyber-attacks and any such attacks could result in losses described above as well as disputes with physicians, patients and our partners,
regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which
could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows.<br>
</p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"></p>




<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0pt 10pt; text-align: center"><b>Risks Attendant to Our Management and
Corporate Governance</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>We have a limited staff. This situation makes it difficult
to implement proper internal controls over financial reporting and to develop and implement long term strategies.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Having only limited staff makes it difficult for us to establish
corporate governance practices, including disclosure controls and procedures, and to manage internal control over financial reporting.
With limited staff, we need to outsource these and other matters, leading to reliance on third parties. Faulty judgments, errors or mistakes,
or the failure to adhere to established controls and procedures by such third parties may make it difficult for us to ensure that the
objectives of the control system are met. A failure of our controls and procedures to detect other than inconsequential errors or fraud
could seriously harm our business.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b><i>The elimination of monetary liability against our directors, officers
and employees under our Bylaws and the existence of indemnification rights to our directors, officers and employees under our Articles
of Incorporation may result in substantial expenditures by our company and may discourage lawsuits against our directors, officers and
employees.</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">Our Bylaws contain provisions that limit the liability of our directors
and officers for monetary damages to our company and shareholders. Our Articles of Incorporation also require us to indemnify our officers
and directors against claims arising from their service as such. The foregoing indemnification obligations could result in our company
incurring substantial expenditures to cover the cost of settlement or damage awards against directors, officers and employees that we
may be unable to recoup. These provisions and resulting costs may also discourage our company from bringing a lawsuit against directors
or officers for breaches of their fiduciary duties, and may similarly discourage the filing of derivative litigation by our shareholders
against our directors and officers even though such actions, if successful, might otherwise benefit our company and shareholders.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><b>Risks Attendant to Regulatory Approval and
Other Legal Compliance Matters</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>We may be unable to obtain U.S. or foreign regulatory approvals
and, as a result, may be unable to commercialize our product candidates. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Rigorous preclinical testing and clinical trials and an extensive
regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug or
device can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated
delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and
obtain the regulatory approvals necessary for us to begin selling them.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">As a company, we have not conducted any pre-clinical studies
or clinical trials of any product candidates, nor have we managed the regulatory approval process with the FDA or any other
regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable and
requires successful completion of extensive clinical trials which typically takes many years, depending upon the type, complexity
and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial
data can and often changes during product development, which makes it difficult to predict with any certainty how they will be
applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation
or administrative action, or changes in FDA policy during the period of drug development, clinical trials and FDA regulatory
review.</p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Any delay or failure in seeking or obtaining required approvals
would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing
and seeking approval. Furthermore, any regulatory approval to market a drug or device may be subject to significant limitations on the
approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority
to require a REMS as part of approving an NDA, or after approval, which may impose further requirements or restrictions on the distribution
or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers
that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients
to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the product and affect
reimbursement by third-party payors.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>Even if our product candidates receive regulatory approval,
they will be subject to significant post-marketing regulatory requirements and oversight. Additionally, our product candidates, if approved,
could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if
we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any
of them are approved. </i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Following any regulatory approvals, our products will be subject
to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy,
approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of medical
products and devices. Any regulatory approvals that we may receive for our product candidates will require the submission of reports to
regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations
related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval
study or risk management requirements.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">We also cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example,
certain policies of the current U.S. administration may impact our business and industry. Namely, the current U.S. administration has
taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or
otherwise materially delay, the FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes
through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive
actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA’s ability to exercise
its regulatory authority. If these executive actions impose constraints on FDA’s ability to engage in oversight and implementation
activities in the normal course, our business may be negatively impacted.</p>


<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt">If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial
condition and results of operations.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><b>Item 1B. Unresolved Staff
Comments</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Not applicable.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"><b>Item 2. 	Properties</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>


<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Healthtech Solutions' executive offices are
located at 181 Dante Avenue, Tuckahoe, New York 10707. The offices are provided by our corporate secretary free of charge.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Our subsidiary, Healthtech Wound Care, Inc.,
is currently leasing offices that include a laboratory in Salt Lake City for approximately $32,000 per month. We expect to enter into
a formal lease for the premises in the near future. That property will be adequate for the operations of Healthtech Wound Care, Inc. for
the foreseeable future.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Item 3.	Legal Proceedings</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">None.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Item 4.	Mine Safety Disclosures.</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not Applicable.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>PART II</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>Item 5. Market For Registrant’s Common Equity, Related Stockholder
Matters And Issuer Purchases Of Equity Securities.</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>(a) Market Information</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The Company’s common stock is quoted on
the OTC Pink Market under the symbol "HLTT". The quotations reported on the OTC Pink Market reflect inter-dealer prices without
retail markup, markdown or commissions, and may not necessarily represent actual transactions.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The Company's common stock is thinly traded.
The quoted bid and asked prices for the Common Stock vary significantly from week to week. An investor holding shares of the Company's
Common Stock may find it difficult to sell the shares and may find it impossible to sell more than a small number of shares at the quoted
bid price.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>(b) Shareholders</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Our shareholders list contains the names of
153 stockholders of record of the Company’s Common Stock.</p>


<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>(c) Dividends</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b>&nbsp;</b>The Company has never paid or declared
any cash dividends on its Common Stock and does not plan to do so in the foreseeable future. The Company intends to retain any future
earnings for the operation and expansion of the business. Any decision as to future payment of dividends will depend on the available
earnings, the capital requirements of the Company, its general financial condition and other factors deemed pertinent by the Board of
Directors.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>(d) Securities Authorized for Issuance
Under Equity Compensation Plans</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The Company had no securities authorized for
issuance under equity compensation plans as of December 31, 2020.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>(e) Sale of Unregistered Securities</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The Company did not make any sale of unregistered
securities during the 4<sup>th</sup> quarter of fiscal year 2021.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>(f) Repurchase of Equity Securities</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The Company did not repurchase any shares of its common
stock during the 4<sup>th</sup> quarter of fiscal year 2021.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.75in"><b>Item 7.</b></td><td><b>Management’s Discussion and Analysis of Financial Condition and Results of Operations</b></td></tr></tbody></table>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt"><b>Results of Operations</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 45pt; text-indent: -45pt"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">On November 16, 2020,
Healthtech Solutions, Inc. acquired all of the capital stock of Medi-Scan, Inc. in exchange for Series A Preferred Stock that at that
time represented 97% of the equity in Healthtech Solutions. Because the transaction is classified as a reverse merger under GAAP, the
financial results presented in this Report for the period prior to November 16, 2020 are the financial results of MediScan for that period.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">******************************</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The primary focus of our operating activities during
2021 was Varian Biopharmaceuticals, Inc. After two months of negotiations, we acquired Varian in May 2021 in exchange for shares of our
Series C Preferred Stock, which was designed to facilitate the entry of Varian into our incubator model and its later departure from the
incubator. We disposed of Varian in November 2021 by returning the capital stock of Varian to its original shareholders, who in turn delivered
to us the Series C shares as well as 5.5% of the capital stock of Varian. The capital stock of Varian that we own is reflected on out
balance sheets as “investment in and advance to non-consolidated affiliate”.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our ownership and control of Varian during 2021 is
reflected on our Statements of Operations as a Loss from Discontinued Operations. Specifically, we recorded $668,960 as our 100% share
of the loss realized by Varian during the six month period when we owned it. We also separately disclosed the $134,111 loss that we realized
as a result of disposing of Varian, being the amount of our investment in Varian that was not recovered.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>


<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our loss from operations for 2021 and 2020 was attributable
primarily to the administrative expenses incurred as we developed the infrastructure and relationships necessary to effectively implement
the incubator model that is the core of our business plan.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">The largest item contributing
to our loss from operations was general and administrative expenses attributable to related parties, which totaled $2,595,132 in 2021,
compared to $129,733 in 2020. The bulk of the 2021 expense - $2.2 million – represented the then-market value of four million shares
of our common stock that were issued to two of our directors and our general counsel in November 2021. The shares were issued in the wake
of our disposal of Varian because extraordinary efforts would be required from these three individuals to refocus Healthtech’s development,
efforts for which we had no other means of compensating these individuals, having substantially exhausted our cash resources sustaining
Varian.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">The remainder of the
general and administrative expenses were primarily attributable to compensation (cash and stock) of the group of consultants who represent
our labor force, legal and accounting expenses (particularly high due to acquisitions and several aborted efforts at acquisitions), office
expenses, public relations expenses, and other expenses related to our efforts to bring Healthtech to the level of an effective incubator.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">The research and development
activities relating to MediScan and RevHeart caused us to incur $481,772 in expenses during 2021 (including $322.000 accrued due to activities
of related parties), a modest increase over the $425,833 that we incurred during 2020 in connection with research and development by MediScan.
The increase was primarily attributable to the organization of RevHeart early in 2021 and the initiation of its research activities. We
expect that our research and development expenses will rise significantly if we obtain the capital resources necessary to fully implement
our business plan. In particular, the effort to bring MediScan’s technology to market will require several million dollars of capital
investment.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">As a result of the
expenses described above, we realized in 2021 a loss from operations totaling $5,005,268. Our operations in 2020 resulted in a loss of
$709,858.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white; text-indent: 0.5in">In the fall of 2020,
prior to our reverse merger, MediScan sold 7% Convertible Debentures to obtain capital. In connection with the reverse merger, the MediScan
debentures were exchanged for 7% Convertible Debentures issued by Healthtech Solutions. Healthtech Solutions then sold additional Debentures,
with the result that by spring of 2021 the principal and accrued interest on the Debentures totaled $803,715. In May 2021 we exchanged
common stock with the holders of the Debentures to fully satisfy the Debentures.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We accounted for our convertible debt in
accordance with ASC 815, <i>Derivatives and Hedging</i> as the conversion feature embedded in the convertible debentures could have
resulted in the debenture principal and related accrued interest being converted to a variable number of our common shares. The
conversion feature on these debentures was variable and based on trailing market prices. It therefore contained an embedded
derivative. The fair value of the conversion feature was calculated when the debentures were issued, and we recorded a debenture
discount and derivative liability for the calculated value. We recognized interest expense for accretion of the debenture discount
over the term of the note. The conversion liability was valued at the end of the reporting period and resulted in loss for the
change in fair value. Among the reasons why we negotiated a cancellation of the Debentures in exchange for common stock was that the
volatile price of our stock meant that the gain or loss realized due to the Debentures could often be material to our results.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Accounting for the Convertible Debentures, as described
above, we realized a derivative expense of $2,933,735 in 2021. We also recorded $367,144 in interest expense, most of which was attributable
to the debentures. After taking these Other Expenses into account, we realized a net loss from continuing operations of $8,306,147 ($0.28
per share) in 2021. After taking into account our loss as a result of the investment in Varian, our net loss for 2021 was $9,109,218 ($0.31
per share). Our net loss for 2020 was $732,208 ($0.61 per share).</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>Liquidity <span style="color: #262626">and Capital Resources</span></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white; text-indent: 0.5in">Our company is designed
to function as an incubator for development stage medical technology enterprises. During 2021 and 2020 our statements of cash flows reflected
that design: in each year we raised capital from the sale of securities and used approximately the amount of cash raised to fund medical
research. Our administrative expenses, albeit representing a large portion of our loss in each year, were primarily paid for by issuance
of common stock.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; background-color: white">In 2021, the operating
activities of our continuing operations used $1,224,799 in cash, despite the net loss from continuing operations of $8,440,259 that we
recorded for the year. The difference was primarily attributable to the $2,933,735 in expenses that we incurred in relation to our conversion
of convertible debentures and the $3,229,028 in compensation expense that we incurred as a result of issuance of our common stock to management
and consultants. In 2020, when our operations were exclusively focused on MediScan, the $531,446 of cash that we used in operations differed
from our net loss primarily because we borrowed $105,754 from related parties in that year.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">At December 31, 2021 Healthtech
Solutions had a working capital deficit of $757,563, representing a decline of $812,598 in working capital during 2021. The decline occurred
because we increased our accrued expenses and accounts payable by a total of $653,575 and the net cash provided by our financing activities
during 2021 was $121,891 short of the net cash used in our continuing operating activities and net cash used in investing activities.
The underlying reason for the decline in working capital was our cash investment in the operations of Varian, which was reduced to a $110,000
asset on our balance sheet when we returned Varian to its original shareholders in November 2021. As a result, by the 4<sup>th</sup> quarter
of 2021 we had eliminated most of the cash reserves we accumulated in the first half of 2021 and were funding ongoing operations by borrowing
from our shareholders.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The cash requirements of our business plan are intense.
To attract exciting additions to our portfolio, we must be able to offer each the several million dollars of financing that is necessary
to bring a medical technology to a stage where its sponsor can function independently. Since our ambition is to sustain a portfolio of
such enterprises, our near term capital requirements (near term being the two to three years before we can anticipate initial returns
on our investments) will be tens of millions of dollars. &nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white; text-indent: 0.5in">Note 3 to our
2021 consolidated financial statements discloses that the financial condition of Healthtech Solutions raises substantial doubt as to
the Company's ability to continue as a going concern. Management intends to pursue one or more offerings of securities in order to
obtain the funds that will be necessary for successful implementation of our business plan. At present, however, no commitments for
future funding have been received.</p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; background-color: white"><b>Application of Critical Accounting
Policies</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In preparing our financial statements we are required to formulate
working policies regarding valuation of our assets and liabilities and to develop estimates of those values.&nbsp;&nbsp;In our preparation
of the financial statements for the years ended December 31, 2021 and 2020, there were two estimates made which were (a) subject to a
high degree of uncertainty and (b) material to our results.&nbsp;These were:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 54px">&nbsp;</td>
    <td style="vertical-align: top; text-align: center; width: 24px; padding-bottom: 10pt"><span style="font-size: 16pt"><b>·</b></span></td>
    <td style="padding-bottom: 10pt">Our determination of the fair value of the derivative liability embedded in the 7% Convertible Debentures. We based the determination of fair value on certain assumptions specified in Note 9 to our Financial Statements. Application of those assumptions led us to record a derivative expense of $2,933,735 for 2021 and a change in fair value of derivative liability of $2,773 for 2020.</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tbody><tr style="vertical-align: top">
    <td style="width: 54px">&nbsp;</td>
    <td style="text-align: center; width: 24px; padding-bottom: 10pt"><span style="font-size: 16pt"><b>·</b></span></td>
    <td style="padding-bottom: 10pt">Our determination to record as $60,000 the fair value of the 5.5% interest in Varian Biopharmaceuticals that we received in November 2021. This determination was based on the financial condition of Varian at that time and the absence of objective criteria for attributing fair value to its technology. As a result, our investment in Varian was fully expensed in our 2021 financial statements. </td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>Impact of Accounting Pronouncements</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><i>&nbsp;</i>There were no recent accounting
pronouncements that have or will have a material effect on the Corporation’s financial position or results of operations.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: -1in"><b>Item 7a Quantitative And Qualitative Disclosures
About Market Risk.</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt 1in; text-indent: -0.5in">Not Applicable.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt"><b>Item 8. Financial Statements</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="border-bottom: black 1pt solid">Page</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&nbsp;</td>
    <td>F-1</td>
    <td>Report of Independent Registered Public Accounting Firm </td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&nbsp;</td>
    <td>F-2</td>
    <td>Consolidated Balance Sheets as of December 31, 2021 and 2020.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 4px">&nbsp;</td>
    <td style="width: 96px">F-3</td>
    <td>Consolidated Statements of Operations for the Years Ended December 31, 2021 and 2020.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&nbsp;</td>
    <td>F-4</td>
    <td>Consolidated Statement of Changes in Stockholders’ (Deficiency) Equity for the Years Ended December 31, 2021 and 2020.</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&nbsp;</td>
    <td>F-5</td>
    <td>Consolidated Statement of Cash Flows for the Years Ended December 31, 2021 and 2020.</td></tr>

<tr style="vertical-align: top; background-color: white">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td>&nbsp;</td>
    <td>F-6 to F-16</td>
    <td>Notes to Financial Statements.</td></tr>
  </tbody></table>
<p style="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 6pt"><b>&nbsp;</b></p>


<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span style="text-decoration: underline">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&nbsp;&nbsp;</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Board of Directors and Stockholders of</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Healthtech Solutions, Inc.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><b>Opinion on the Financial Statements</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">We have audited the accompanying consolidated balance
sheets of Healthtech Solutions, Inc.(the Company) as of December 31, 2021 and 2020, and the related consolidated statements of operations,
changes in stockholders’ deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the
financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position
of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity
with accounting principles generally accepted in the United States of America.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><b>Going Concern</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: justify">As discussed in Note 3 to the accompanying consolidated
financial statements, the accompanying financial statements have been prepared in conformity with accounting principles generally accepted
in the United States, which contemplate continuation of the Company as a going concern. The Company has not generated any revenue since
inception and has an accumulated deficit of $10,547,924 as of December 31, 2021. These factors, among others, raise substantial doubt
about the ability of the Company to continue as a going concern. Continuation as a going concern is dependent on the ability to raise
additional capital and financing, though there is no assurance of success. Management’s plans in regard to these matters are also
described in Note 3 to the accompanying financial statements.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify"><b>Basis for Opinion</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s
internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 6pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; color: #212529"><b>Critical Audit Matters</b></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 6pt 35pt 6pt 0; text-align: justify">Critical audit matters are matters arising
from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee
and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments. We determined that there were no critical audit matters.</p>

<p style="font: 9pt/10.7pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 9pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<span id="xdx_90E_edei--AuditorName_c20210101__20211231_z6xWIWAfOSH7"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorName" inside-table="false" id="fact-identifier-30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Prager Metis CPA’s LLC</ix:nonnumeric></span></span></span></p>

<p style="font: 9pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 8pt">We have served as the Company’s auditor since 2020</p>

<p style="font: 9pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">Hackensack, <span id="xdx_908_edei--AuditorLocation_c20210101__20211231_zTEQkozPtgC6"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorLocation" inside-table="false" id="fact-identifier-31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">New Jersey</ix:nonnumeric></span></span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0">April 15, 2022 <span id="xdx_904_edei--AuditorFirmId_c20210101__20211231_zYORT4ZUMSL6" style="display: none"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="dei:AuditorFirmId" inside-table="false" id="fact-identifier-32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273</ix:nonnumeric></span></span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span></span></b></span></p>


<!-- Field: Page; Sequence: 30; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b></b></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HEALTHTECH
    SOLUTIONS INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
    BALANCE SHEETS</b></span></td></tr>
  </tbody></table>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b>&nbsp;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_zpx4Ks8ktQ2k" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" id="xdx_495_20211231" style="font-weight: bold; text-align: center">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td colspan="3" id="xdx_494_20201231" style="font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31, 2021</span></td><td style="font-weight: bold"><span style="font-size: 10pt">&nbsp;</span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font-size: 10pt">December 31, 2020</span></td></tr>
  <tr id="xdx_408_eus-gaap--AssetsCurrentAbstract_iB_zAf8lxzJEIGj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Current Assets:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maCzSEV_zemyEzcCr2i9" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; padding-left: 10pt"><span style="font-size: 10pt">Cash</span></td><td style="width: 8%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,105</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="width: 8%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-34" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,996</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PrepaidExpenseCurrent_i01I_maCzSEV_zUhVONxUZsLk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Prepaid expenses</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,997</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PrepaidExpenseCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_401_eus-gaap--LoansReceivableHeldForSaleAmount_i01I_d0_maCzSEV_zVJfKp5ekHP4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Loan receivable</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LoansReceivableHeldForSaleAmount" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168,000</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LoansReceivableHeldForSaleAmount" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsCurrent_iTI_mtCzSEV_maAzDWG_zDSRQHHBeLG5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Total Current Assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">313,102</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AssetsCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-40" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138,996</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AssetsNoncurrentAbstract_iB_zTeKHvCKjMT2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Long Term Assets:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--DueFromAffiliateNoncurrent_i01I_d0_maANzQ9U_zBRcdbstfpYe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Investment in and advance to
    non-consolidated affiliate</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DueFromAffiliateNoncurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110,000</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DueFromAffiliateNoncurrent" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_402_ecustom--TotalLongTermAssets_iTI_d0_mtANzQ9U_maAzDWG_zrmCSLOFKh0i" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Total Long Term Assets</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="hltt:TotalLongTermAssets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">110,000</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="hltt:TotalLongTermAssets" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_d0_maAzDWG_zmIjEbABUcya" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Intangible assets net of accumulated
    amortization</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-46" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,926</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_mtAzDWG_znj30KNTSr0h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total Assets</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">423,102</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Assets" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">164,922</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrentAbstract_iB_zGMmeu6iPXl4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Current Liabilities:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_i01I_maCzTMB_zalMKaDPiZuc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Accounts payable and accrued expenses</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">733,743</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">80,169</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPayableCurrent_i01I_d0_maCzTMB_zCHkUxlLS3h6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Accrued interest</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:InterestPayableCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,792</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40B_ecustom--LoansFromShareholders_i01I_d0_maCzTMB_zYXxzyq2ROsb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Loans from shareholders</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="hltt:LoansFromShareholders" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">336,921</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="hltt:LoansFromShareholders" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesCurrent_iTI_mtCzTMB_maCz2gw_zl6CdGQIbXai" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Total Current Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-55" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,070,665</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesCurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">83,961</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesNoncurrentAbstract_iB_zwo8Sb7DvX24" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Long Term Liabilities:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ConvertibleDebtNoncurrent_i01I_pp0p0_d0_maCzLw9_zdkaVeJeTU1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Convertible debentures payable, net of discount</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-57" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ConvertibleDebtNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">305,684</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_404_eus-gaap--DerivativeLiabilitiesNoncurrent_i01I_d0_maCzLw9_zVLKyXEHWkqj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Derivative liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:DerivativeLiabilitiesNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">337,874</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesNoncurrent_iTI_d0_mtCzLw9_maCz2gw_zCbk974qGOYj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Total Long Term Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesNoncurrent" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesNoncurrent" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">643,558</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--Liabilities_iTI_pp0p0_mtCz2gw_maCzw5T_zx5Z9BUPZ5Jc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Total&nbsp;&nbsp;Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,070,665</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:Liabilities" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">727,519</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_iB_zY1sCy7JXhDg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Stockholders' Equity (Deficit):</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i01I_maCzm8G_zHshyN7BGQu8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Series A preferred stock, $<span id="xdx_90B_eus-gaap--PreferredStockParOrStatedValuePerShare_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Series A Preferred Stock, par value per share"><span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Series A Preferred Stock, par value per share"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value, <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Series A Preferred Stock,shares authorized"><span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Series A Preferred Stock,shares authorized"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesAuthorized" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span>
    authorized, <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Series A Preferred Stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Series A Preferred Stock,shares outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-69" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2021-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110,520</ix:nonfraction></span></ix:nonfraction></span></span></span> and <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Series A Preferred Stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_pdd" title="Series A Preferred Stock,shares outstanding"><span><ix:nonfraction name="us-gaap:PreferredStockSharesIssued" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-71" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:PreferredStockSharesOutstanding" contextref="AsOf2020-12-31_us-gaap_SeriesAPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-72" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">156,837</ix:nonfraction></span></ix:nonfraction></span></span></span> issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PreferredStockValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">157</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--CommonStockValue_i01I_pp0p0_maCzm8G_zqRA47Fpfks9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Common stock, $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_c20211231_pdd" title="Common stock, par value per share"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value per share"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.001</ix:nonfraction></span></ix:nonfraction></span></span></span> par value, <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_c20211231_pdd" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, shares authorized"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-77" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesAuthorized" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-78" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000,000</ix:nonfraction></span></ix:nonfraction></span></span></span> shares
    authorized, <span id="xdx_901_eus-gaap--CommonStockSharesIssued_c20211231_pdd" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_c20211231_pdd" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-79" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,965,933</ix:nonfraction></span></ix:nonfraction></span></span></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_c20201231_pdd" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common stock, shares outstanding"><span><ix:nonfraction name="us-gaap:CommonStockSharesIssued" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction name="us-gaap:CommonStockSharesOutstanding" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-82" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,701,269</ix:nonfraction></span></ix:nonfraction></span></span></span> issued and outstanding as of December, 2021 and December 31, 2020, respectively</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,966</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CommonStockValue" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,701</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdditionalPaidInCapital_i01I_maCzm8G_zkw7zejVOw77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Additional paid-in capital</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,833,286</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AdditionalPaidInCapital" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">866,251</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzm8G_zbGctptaKlP5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Accumulated deficit</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-87" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,547,924</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,438,706</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockholdersEquity_iTI_mtCzm8G_maCzw5T_z5LYiYR69v4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 10pt">Stockholders' Equity (Deficit):</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">647,563</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">562,597</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzw5T_z8lGhh7WULJe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"><span style="font-size: 10pt">Total Liabilities and Stockholders'
    Equity (Deficit)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">423,102</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">164,922</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b></b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><b>&nbsp;</b></p>



<p style="font: 20pt Arial, Helvetica, Sans-Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HEALTHTECH
    SOLUTIONS INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
    STATEMENTS OF OPERATIONS</b></span></td></tr>
  </tbody></table>

<p style="font: 20pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<table cellpadding="0" cellspacing="0" id="xdx_30E_113_zsPk8BCgv345" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49F_20210101_20211231" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_49D_20200101_20201231" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Years Ended</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br>2021</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, <br>2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: right">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--Revenues_d0_maCzUhP_z39vzqi5OTc8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt">Revenue</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:Revenues" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_zkZTatVCfum6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating Expenses:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td style="font-weight: bold">&nbsp;</td>
    <td style="font-weight: bold; text-align: left">&nbsp;</td><td style="font-weight: bold; text-align: right">&nbsp;</td><td style="font-weight: bold; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maCzUhL_zk9Yk1bNbkg4" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 10pt">General and administrative</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-95" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,902,438</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 8%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 12%; text-align: right"><span><ix:nonfraction name="us-gaap:GeneralAndAdministrativeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">115,403</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherGeneralAndAdministrativeExpense_i01_maCzUhL_zz4HWMts7KEf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative-related party</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,595,132</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-98" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">129,733</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzUhL_zKLla1hk2m53" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">159,772</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ResearchAndDevelopmentExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-100" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">348,773</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_ecustom--ResearchAndDevelopmentRelatedParty_i01_maCzUhL_zAvcBVVnXnQ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development – related party</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="hltt:ResearchAndDevelopmentRelatedParty" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-101" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">322,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="hltt:ResearchAndDevelopmentRelatedParty" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">77,060</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentForAmortization_i01_maCzUhL_zyHkOSQcFhU4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Amortization</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentForAmortization" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-103" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,926</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentForAmortization" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-104" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,889</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40F_eus-gaap--OperatingExpenses_iT_mtCzUhL_msCzUhP_zlAeHNTxdh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Total Operating Expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,005,268</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:OperatingExpenses" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">709,858</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingIncomeLoss_iT_mtCzUhP_maCzy6V_zD6FKU51HuYg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from Operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-107" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,005,268</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:OperatingIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-108" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">709,858</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zMEbPWhtOjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other Expenses (Income):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestIncomeExpenseNet_i01_maCzJ3q_zdNm07d0uPah" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeExpenseNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-109" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">367,144</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:InterestIncomeExpenseNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,577</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40D_eus-gaap--GainLossOnSaleOfDerivatives_i01N_di_maCzJ3q_z7oazdADwrJc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Change in fair value of derivative liabilities</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:GainLossOnSaleOfDerivatives" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,933,735</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:GainLossOnSaleOfDerivatives" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,773</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_iT_mtCzJ3q_maCzy6V_z3uzLbN44wCl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total Other Expenses</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-113" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,300,879</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:NonoperatingIncomeExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-114" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,350</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_iT_mtCzy6V_maCz9MY_zIh42tQZppBd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from continuing operations before tax provision</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,306,147</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">732,208</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxExpenseBenefit_d0_msCz9MY_zRwirsCOGBce" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Provision for income tax</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-117" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:IncomeTaxExpenseBenefit" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-118" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_mtCz9MY_maNILz7a6_zSESsOHUk083" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from continuing operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,306,147</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-120" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">732,208</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_iB_zd5FzVxJ7kxf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from Discontinued Operations:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_i01_d0_maILFDOzi9R_zAywLSyma0ek" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss from Discontinued Operations, net of taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-121" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">668,960</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-122" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_i01_d0_maILFDOzi9R_zH5Jzi8gGXG" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Loss from disposal</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-123" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,111</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-124" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_408_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_i01_mtILFDOzi9R_maNILz7a6_zJsM6A0QKST4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Total Loss from Discontinued Operations:</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="hltt:IncomeLossFromDiscontinuedOperationNetOfTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-125" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">803,071</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--ProfitLoss_iT_mtNILz7a6_zSZNGIf6jgal" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-126" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,109,218</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-127" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">732,208</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_ecustom--LossFromContinuingOperationsPerCommonShareBasicAndDiluted_z5F57inRdz8j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from continuing operations per common share - basic and diluted</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="hltt:LossFromContinuingOperationsPerCommonShareBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-128" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.28</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="hltt:LossFromContinuingOperationsPerCommonShareBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-129" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.61</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--LossFromDiscontinuedOperationsPerCommonShareBasicAndDiluted_d0_zFHRr3zYqIC2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Loss from discontinued operations per common share - basic and diluted</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="hltt:LossFromDiscontinuedOperationsPerCommonShareBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.03</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="hltt:LossFromDiscontinuedOperationsPerCommonShareBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="INF" unitref="USDPShares" inside-table="true" id="fact-identifier-131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_ecustom--NetLossPerShareBasicAndDiluted_zrB9FdimeDha" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss per share - basic and diluted</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="hltt:NetLossPerShareBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-132" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.31</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="hltt:NetLossPerShareBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="USDPShares" inside-table="true" id="fact-identifier-133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.61</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_403_ecustom--WeightedAverageSharesOutstandingBasicAndDiluted_zmaNA3cZSTud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average shares outstanding Basic and diluted</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="hltt:WeightedAverageSharesOutstandingBasicAndDiluted" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,430,180</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="hltt:WeightedAverageSharesOutstandingBasicAndDiluted" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,198,321</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt; text-align: center">&nbsp;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</span>&nbsp;</p>


<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HEALTHTECH
    SOLUTIONS INC.</b></span></td></tr>
  <tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
    STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIENCY) EQUITY</b></span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>


<table cellpadding="0" cellspacing="0" id="xdx_305_114_zdCfleYRaOD" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIENCY) EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zNmXEYMSN7Fd" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_custom--SeriesAPreferredStocksMember_ztvJUZkt6bqe" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zgtiAyhwCi96" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zanN9GPClv2f" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_4B4_zpokjL7WFwI3" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Common Stock</span></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</td><td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Series A</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Preferred Stock</span></p></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center"><b>Total</b></td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1pt">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Number of Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Additional Paid-In Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">Accumulated Equity (Deficit)</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt"> Stockholders' Equity (Deficit)</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_43E_c20200101__20201231_eus-gaap--StockholdersEquity_iS_z4PcXbqdD7Dc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 37%">Balance at December 31, 2019</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKa9a1FjiMkh" title="Beginning balance, shares" style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0250"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" id="fact-identifier-136" unitref="Shares" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0244"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_CommonStockMember" id="fact-identifier-137" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0244" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAPreferredStocksMember_zJUIzvfmXmTc" title="Beginning balance, shares" style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2019-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-138" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">156,837</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">157</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-140" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">840,510</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">706,498</ix:nonfraction></span></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 5%; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-142" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,169</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of reverse merger transaction</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesOther_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCDQnyll5Sre" title="Effect of reverse merger transaction, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-143" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,701,269</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,701</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-145" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">244,701</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">235,000</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Capital contributions</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0262"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-147" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0263"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-148" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">270,442</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0265"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-150" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">270,442</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_CommonStockMember" id="fact-identifier-152" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0269"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-153" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-154" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-155" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">732,208</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-156" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">732,208</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20210101__20211231_eus-gaap--StockholdersEquity_iS_zaZbdYwCfWmi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at&nbsp;December 31, 2020</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQkEFJFtDC7b" title="Beginning balance, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,701,269</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-158" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,701</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAPreferredStocksMember_zTSW13tUmQN8" title="Beginning balance, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2020-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">156,837</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-160" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">157</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-161" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">866,251</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-162" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,438,706</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-163" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">562,597</ix:nonfraction></span></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_iP3us-gaap--StockIssuedDuringPeriodValueOther_zPyk0HByJwEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock for services</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_iP3us-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyQBv4WvRowj" title="Issuance of common stock for services, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,975,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-165" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,975</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0285"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-166" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-167" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,224,053</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,229,028</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_iP3us-gaap--StockIssuedDuringPeriodSharesIssuedForServices_zmWL3n8njiX6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock for cash proceeds</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEU22biFcDJb" title="Issuance of common stock for cash proceeds, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-169" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,962,500</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-170" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,963</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0293"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-171" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-172" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,783,537</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0295"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-173" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-174" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,792,499</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--DebtConversionOriginalDebtAmount1_iP3us-gaap--StockIssuedDuringPeriodSharesNewIssues_zowc8BfvJTyg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of Series A Preferred into common stock</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zm4yBVzUU8O7" title="Conversion of Series A Preferred into common stock, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-175" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,820,000</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,820</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesOther_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAPreferredStocksMember_z4jjPzVE407i" title="Conversion of Series A Preferred into common stock, shares" style="text-align: right">(<span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitref="Shares" inside-table="true" id="fact-identifier-177" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">46,317</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">47</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<span><ix:nonfraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-179" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,773</ix:nonfraction></span></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303"><span><ix:nonfraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-180" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0304"><span><ix:nonfraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextref="From2021-01-01to2021-12-31" id="fact-identifier-181" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--ConversionOfStockAmountIssued1_iP3us-gaap--StockIssuedDuringPeriodSharesOther_zp8JHGlo04ta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of Debentures into common stock</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--ConversionOfStockSharesConverted1_iP3us-gaap--ConversionOfStockAmountIssued1_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2F2YXZgVZIh" title="Conversion of Debentures into common stock, shares" style="text-align: right"><span><ix:nonfraction name="us-gaap:ConversionOfStockSharesConverted1" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-182" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,507,164</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConversionOfStockAmountIssued1" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-183" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,507</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0311"><span><ix:nonfraction name="us-gaap:ConversionOfStockAmountIssued1" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-184" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConversionOfStockAmountIssued1" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-185" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,994,660</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0313"><span><ix:nonfraction name="us-gaap:ConversionOfStockAmountIssued1" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-186" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:ConversionOfStockAmountIssued1" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-187" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,998,167</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_z1kiFXlIVLr3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Capital contributions</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-188" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0319"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-189" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,558</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0321"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" id="fact-identifier-191" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-192" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,558</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zjcY6yRB9zXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_CommonStockMember" id="fact-identifier-193" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0325"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_custom_SeriesAPreferredStocksMember" id="fact-identifier-194" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0326"><span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="fact-identifier-195" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-012021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-196" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,109,217</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="us-gaap:NetIncomeLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-197" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,109,217</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20210101__20211231_eus-gaap--StockholdersEquity_iE_zJRQlWFNkh3f" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at&nbsp;December 31, 2021</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNuHYHyMJlx6" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-198" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,965,933</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,966</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--SeriesAPreferredStocksMember_zJBGVlvZPE99" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-200" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110,520</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-201" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-202" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,833,286</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,547,923</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<span><ix:nonfraction name="us-gaap:StockholdersEquity" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-204" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">647,563</ix:nonfraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </tbody></table>


<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these consolidated financial statements</span>&nbsp;&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>



<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HEALTHTECH
    SOLUTIONS INC.</b></span></td></tr>
  <tr>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED
    STATEMENTS OF CASH FLOWS</b></span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_112_zdDz9lRBjqK6" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_496_20210101__20211231_zlB8Ca1Jef92" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_491_20200101__20201231_z8dP0pahSpnh" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td colspan="5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">For
                                            the Years Ended</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December
                                            31, 2021</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 10pt">December
                                            31, 2020</span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zfbOA6Z9V0z7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Cash flows from operating activities</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--ProfitLoss_i01_maCzdUZ_zreydZhN5BR9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Net loss</span></td><td style="width: 8%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-205" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,109,218</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td><td style="width: 8%"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 10pt">$</span></td><td style="width: 12%; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:ProfitLoss" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-206" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">732,208</ix:nonfraction></span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_i01N_di0_maCzdUZ_z20HPgdEIURe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Net loss from discontinued operations</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">668,960</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IncomeLossFromContinuingOperations_i01_maCzdUZ_zAfccKiTSMbc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Net loss from continuing operations</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:IncomeLossFromContinuingOperations" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-209" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,440,258</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zDGBYBgczsnc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Adjustments to Reconcile Net Loss to Net Cash used
    in operating activities:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--AdjustmentForAmortization_i02_maCzdUZ_zw9eF9TvYg0l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Amortization expense</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AdjustmentForAmortization" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-210" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,926</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AdjustmentForAmortization" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-211" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,889</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40B_ecustom--IssuanceOfCommonStock_i02_d0_maCzdUZ_z3o7NPKAxPNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Issuance of common stock</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="hltt:IssuanceOfCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-212" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,229,028</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="hltt:IssuanceOfCommonStock" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-213" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_401_eus-gaap--GainLossOnSaleOfDerivatives_i02N_di_msCzdUZ_zn3glNL2GFRb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Change in fair value of derivative liability</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:GainLossOnSaleOfDerivatives" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-214" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,933,735</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:GainLossOnSaleOfDerivatives" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-215" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,773</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--GainLossOnDispositionOfAssets1_i02N_di_msCzdUZ_zGnBMibvPoE1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Loss on disposal of subsidiary</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:GainLossOnDispositionOfAssets1" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-216" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,111</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--AmortizationOfDebtDiscountPremium_i02_d0_maCzdUZ_zLnIAJ9QMz35" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Amortization of discount on convertible debentures</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-217" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-218" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,277</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--PaidInKindInterest_i02_d0_maCzdUZ_zXavcjgkd2hb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Interest expense capitalized to convertible debentures
    payable</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PaidInKindInterest" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-219" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:PaidInKindInterest" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-220" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,508</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OtherNoncashExpense_i02_maCzdUZ_zhwdC9fOILWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Non-cash interest</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:OtherNoncashExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-221" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">367,144</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zdCR7tsoPqB4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Changes in operating assets and liabilities:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02_msCzdUZ_zu6qFoEPIIk7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Prepaid expenses</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,059</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-223" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInInterestPayableNet_i02_maCzdUZ_zCqtoQp7QOfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt"><span style="font-size: 10pt">Accrued interest</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInInterestPayableNet" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-224" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,792</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzdUZ_zDbksOuec4T6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 20pt"><span style="font-size: 10pt">Accounts payable and accrued
    expenses</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-225" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">653,575</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-226" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">43,769</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzdUZ_maCz0e4_z1iCY8S1W4Cf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Net cash used in operating activities</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-227" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,224,799</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-228" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">637,200</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zmhqjzjYRkFe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Cash flows from investing activities:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_400_ecustom--AdvancesToDivestedSubsidiary_i01N_di_msNCPBUzioQ_z8eow0shZTaj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Advances to divested subsidiary</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="hltt:AdvancesToDivestedSubsidiary" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-229" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">913,071</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--PaymentsForProceedsFromLoansReceivable_i01N_di_msNCPBUzioQ_zuOuRgrnLlab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Payment of loan receivable</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:PaymentsForProceedsFromLoansReceivable" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-230" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168,000</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfOtherShortTermDebt_i01N_di_msNCPBUzioQ_zmadqJwKYffh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Cash paid upon reverse merger</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:RepaymentsOfOtherShortTermDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-231" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">235,000</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtNCPBUzioQ_maCz0e4_zShcnABRDMNg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Net cash used in investing activities</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,081,071</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-233" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">235,000</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zIoTkifMaBZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Cash flows from financing activities:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_407_ecustom--ProceedsOfLoansFromShareholders_i01_maNCPBUz5bZ_zlVZpSEhN1Qg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Proceeds of loans from shareholders</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="hltt:ProceedsOfLoansFromShareholders" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-234" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">336,921</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="hltt:ProceedsOfLoansFromShareholders" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">105,754</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromConvertibleDebt_i01_pp0p0_maNCPBUz5bZ_zUoIsN31m7j6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Proceeds from convertible debenture</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-236" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ProceedsFromConvertibleDebt" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">625,000</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromContributionsFromParent_i01_maNCPBUz5bZ_zp0POJ6SMdlc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-size: 10pt">Capital contributions</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ProceedsFromContributionsFromParent" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,558</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ProceedsFromContributionsFromParent" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">270,442</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUz5bZ_zFBbAetSQJSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt"><span style="font-size: 10pt">Proceeds from issuance of common
    stock</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-240" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,792,500</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtNCPBUz5bZ_maCz0e4_zFik5MG2i5J6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Net cash provided by financing activities</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-241" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,183,979</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-242" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,001,196</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCz0e4_z336dgkxgwad" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Net increase (decrease) in cash</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">(<span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-243" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">121,891</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">)</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-244" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,996</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_d0_zGGyI1igqBNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 10pt">Cash, beginning of period</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,996</ix:nonfraction></span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2019-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zthnLd8ePzB8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-size: 10pt">Cash, end of period</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,105</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128,996</ix:nonfraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zq2ZGqhgImC4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: right"><span style="font-size: 10pt">&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_404_eus-gaap--InterestPaidNet_i01_d0_zUa3w3Ru4Xtc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Cash paid for interest</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-249" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">61</ix:nonfraction></span></span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:InterestPaidNet" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-250" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesPaid_i01_d0_zwS1zJK5a491" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 10pt">Cash paid for taxes</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaid" contextref="From2021-01-01to2021-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-251" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td><td><span style="font-size: 10pt">&nbsp;</span></td>
    <td style="text-align: left"><span style="font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-size: 10pt"><span><ix:nonfraction name="us-gaap:IncomeTaxesPaid" contextref="From2020-01-012020-12-31" format="ixt:zerodash" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-252" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</span></td><td style="text-align: left"><span style="font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">The accompanying notes
are an integral part of these consolidated financial statements&nbsp;&nbsp;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-253" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_zEPo9flS2lVi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 – <span id="xdx_820_zxMrGy7vNZgh">ORGANIZATION AND NATURE OF BUSINESS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Healthtech Solutions, Inc. (the “Company”) was incorporated
in Utah on October 18, 1985. The Company had no business operations from April 25, 2015, when it spun off its only direct subsidiary,
which at that time owned all of the assets through which the Company was carrying on operations, until November 16, 2020 when the Company
acquired all of the outstanding capital stock of Medi-Scan Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company is pursuing a business plan in which the Company will acquire
and/or invest in cutting edge healthcare technology in the medical device, biopharma and pharmaceutical fields. The goal will be to nurture
these early stage ventures with financial support and administrative and technological assistance until their respective medical solutions
are ready to enter the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Acquisition of Medi-Scan Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Medi-Scan Inc. was organized as a limited liability company named "Medi-Scan
LLC" in the State of Florida on September 25, 2018. On August 25, 2020, Medi-Scan LLC filed articles of conversion with the State
of Florida that converted it from an LLC to a C corporation. In December 2018, Medi-Scan acquired a portfolio of intellectual property
relating to medical imaging. Since December 2018, Medi-Scan has been engaged in developing practical applications for the medical imaging
technology as well as related medical technology. In 2020 Medi-Scan applied for three patents based on the technology developed in the
prior two years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 12, 2020, <span id="xdx_906_ecustom--AgreementDescriptionOfStockExchange_c20201111__20201112__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zSoxuWykqpwc" title="Agreement description"><span><ix:nonnumeric contextref="From2020-11-112020-11-12_custom_ExchangeAgreementMember" name="hltt:AgreementDescriptionOfStockExchange" inside-table="false" id="fact-identifier-254" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">Healthtech Solutions, Inc. entered into an exchange
agreement with Medi-Scan, Inc. ("Medi-Scan") and all of the shareholders of Medi-Scan, pursuant to which the shareholders of
Medi-Scan agreed to transfer all of the issued and outstanding stock of Medi-Scan to Healthtech Solutions, Inc., and Healthtech Solutions,
Inc. agreed to issue to the shareholders of Medi-Scan, Inc. <span id="xdx_904_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20201111__20201112__us-gaap--BusinessAcquisitionAxis__custom--MediScanIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAPreferredsStockMember_pp0d" title="Agreed number of shares issued to shareholders"><span><ix:nonfraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextref="From2020-11-112020-11-12_custom_MediScanIncMember_custom_SeriesAPreferredsStockMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-255" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">156,837</ix:nonfraction></span></span> shares of its Series A Preferred Stock, which at that time represented
<span id="xdx_90E_ecustom--ShareExchangeEquityPercentage_dp_c20201111__20201112__us-gaap--BusinessAcquisitionAxis__custom--MediScanIncMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAPreferredsStockMember_zRZWKj4Qw8ne" title="Share exchange equity percentage"><span><ix:nonfraction name="hltt:ShareExchangeEquityPercentage" contextref="From2020-11-112020-11-12_custom_MediScanIncMember_custom_SeriesAPreferredsStockMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-256" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">97</ix:nonfraction></span></span>% of the equity in Healthtech Solutions. The exchange of equity (the "Share Exchange") was completed on November 16, 2020.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As a result of the Share Exchange, the Medi-Scan shareholders become the
majority shareholders and had control of Healthtech Solutions. The acquisition of Medi-Scan was accounted for as a reverse merger effected
by a share exchange. Healthtech Solutions is considered the legal acquirer and Medi-Scan is considered the accounting acquirer. Accordingly,
the historical financial statements presented in this report for periods prior to November 16, 2020 are those of Medi-Scan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 12, 2020, when the Share Exchange Agreement was executed, the
three members of the Healthtech Solutions Board of Directors were also the three managing members of Medi-Scan, entities under their control
owned a majority of the outstanding capital stock of Medi-Scan, and an entity under the control of one of them owned a majority of the
outstanding capital stock of Healthtech Solutions. Therefore, the Share Exchange was accounted for as a business combination of entities
under common control in accordance with ASC 805-50-30-5. Accordingly, the assets and liabilities of Medi-Scan are presented at their carrying
values at the date of the Share Exchange, and the Company’s historical stockholders’ equity has been retroactively restated
to the first period presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Acquisition/ Disposition of Varian Biopharmaceuticals, Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 7, 2021 HLTT Acquisition Corp., a special purpose vehicle wholly-owned
by Healthtech Solutions, merged into Healthtech Oncology, Inc., a special purpose vehicle formed for the purpose of the merger, which
on that same date acquired the outstanding capital stock of Varian Biopharmaceuticals, Inc. ("Varian") through a non-statutory
share exchange. As a result, Healthtech Oncology became a wholly-owned subsidiary of Healthtech Solutions, and Varian became a wholly-owned
subsidiary of Healthtech Solutions. In exchange for their ownership of Healthtech Oncology, the shareholders of Healthtech Oncology (the
“Varian Shareholders”) received an aggregate of <span id="xdx_90D_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20210501__20210507__us-gaap--BusinessAcquisitionAxis__custom--HealthtechSolutionsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_pp0d" title="Agreed number of shares issued to shareholders"><span><ix:nonfraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextref="From2021-05-012021-05-07_custom_HealthtechSolutionsMember_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-257" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,737</ix:nonfraction></span></span>.184 shares of Series C Preferred Stock issued by Healthtech Solutions.</p>

<ix:exclude><p id="xdx_23E_zT5C8CvhRXt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 35 -->
    <div id="xdx_234_zlENselELYXb" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_233_zqGzoaaXUYD5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_z8ccQJLtwWBa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p>

<ix:exclude><p id="xdx_232_zZpfZJv4TNhl" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zgFLQGcyKI77" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zMK1wWIg4tU4" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_zSyKkOO1nf5l" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>


<ix:exclude><p id="xdx_23A_z1HPWm9Adz66" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_235_zAs7NcsyU908" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zTWfIg7vCPk1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Acquisition/ Disposition of Varian Biopharmaceuticals, Inc. (continued)</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_230_zrL5QavGXAqh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 9, 2021, the Company entered into a Share Exchange Agreement
(the "SEA") with its subsidiaries: Healthtech Oncology and Varian, as well as with the Varian Shareholders. Pursuant to the
SEA, (a) the Varian Shareholders delivered to Healthtech all of the outstanding shares of Healthtech Series C Preferred Stock and (b)
Healthtech caused Healthtech Oncology to transfer to the Shareholders all of the outstanding shares of Varian common stock. At the same
time, Varian issued to Healthtech Varian shares that represent 5.5% of the outstanding shares of Varian upon completion of the share exchange.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 9, 2021, the Company also entered into a Termination and Mutual
Release Agreement with Healthtech Oncology and Varian (the "Termination Agreement"). The Termination Agreement terminated the
Agreement and Plan of Merger and Reorganization among those same parties dated March 30, 2021. The Termination Agreement also included
a provision in which Varian assumed responsibility for payment of certain obligations that Healthtech undertook for the benefit of Varian.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-258" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zTMJimbl7WX8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 – <span id="xdx_827_zaghTtpnMlC1">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zNMBRaaenFP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_860_zGgE99EPSEYg">Basis of Presentation and Consolidation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">These consolidated financial statements have been prepared in accordance
with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying consolidated financial statements reflect the accounts
of Healthtech Solutions, Inc., its wholly owned subsidiaries, Medi-Scan and RevHeart, and the accounts of Varian from May 7, 2021 (date
of acquisition) through November 9, 2021 (date of disposition). All significant inter-company accounts and transactions have been eliminated
in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:UseOfEstimates" inside-table="false" id="fact-identifier-260" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_841_eus-gaap--UseOfEstimates_zAZIVbKvv6b9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_868_zjstum1lhhha">Use of Estimates</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements. Management makes these estimates using the
best information available at the time the estimates are made; however, actual results could differ from those estimates. One significant
item subject to such estimates and assumptions is the valuation of the derivative liabilities. These estimates are often based on complex
judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could
differ from these estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-261" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_849_eus-gaap--ConcentrationRiskDisclosureTextBlock_zSc53nESzZm2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_862_zTYj0iyMHsp7">Concentrations of Credit Risk</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">We maintain our cash in bank deposit accounts, the balances of which at
times may exceed federally insured limits. We continually monitor our banking relationships and have not experienced any losses in our
accounts. We believe we are not exposed to any significant credit risk on cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<ix:exclude><p id="xdx_23B_zSfIAfD8GOS9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 36 -->
    <div id="xdx_233_z1XBoFElkWye" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td id="xdx_231_zxtSAsA9lEq7" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23A_zSzVfxR4hJ3c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_z5GhjjmoqtD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><p id="xdx_233_za63EmQwwwme" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zrcHLCHyJg0d" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zubFapJpTv58" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z0tb0FRMWvV9" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>


<ix:exclude><p id="xdx_230_zQWB4NkcN8Hd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zCxPPYwQU1d5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_844_eus-gaap--ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_zLtQ7JUKjyue" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_86B_zFUHMoXl93f6">Software Development Costs</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with ASC 985-20, the Company expenses software development
costs, including costs to develop software products or the software component of products to be sold, leased, or marketed to external
users, before technological feasibility is reached. Technological feasibility is typically reached shortly before the release of such
products. Software development costs also include costs to develop software to be used solely to meet internal needs and cloud-based applications
used to deliver our services. The Company capitalizes development costs related to these software applications once the preliminary project
stage is complete and it is probable that the project will be completed, and the software will be used to perform the function intended.
Capitalization ends, and amortization begins when the product is available for general release to customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" inside-table="false" id="fact-identifier-263" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_842_eus-gaap--ResearchAndDevelopmentExpensePolicy_zLfugTth28Lg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_860_zMvtcykclYKb">Research and Development</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Research and development costs are expensed when incurred. Research and
development costs include costs of research, engineering, and technical activities to develop a new product or service or make significant
improvement to an existing product or manufacturing process. Research and development costs also include pre-approval regulatory and clinical
trial expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp; &nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-264" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_840_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxUkybjh3oSh" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<b><span id="xdx_867_zpGFewdgLcgg">Intangible Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company reviews goodwill and intangible assets with indefinite lives
for impairment according to the provisions of ASC Topic 350:&nbsp; <i>"Intangibles - Goodwill and Other" </i>at least annually
and when events or changes in circumstances indicate the carrying amount may not be recoverable. The Company measures recoverability of
these assets by comparing the carrying amounts to the future undiscounted cash flows that the assets or the asset group are expected to
generate. If the carrying value of the assets are not recoverable, the impairment recognized is measured as the amount by which the carrying
value of the asset exceeds its fair value. Management has determined that no impairment exists as of December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-265" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_844_eus-gaap--DebtPolicyTextBlock_zFDGXYsI4xxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_860_zAQvgFKkkqJg">Convertible Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company evaluates and accounts for conversion options embedded in convertible
instruments in accordance with ASC 815, Derivatives and Hedging Activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Applicable GAAP requires companies to bifurcate conversion options from
their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria
include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely
related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative
instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as
they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company accounts for convertible instruments (when it has been determined
that the embedded conversion options should not be bifurcated from their host instruments) as follows: the Company records, when necessary,
discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between
the fair value of the underlying common stock at the commitment date of this note transaction and the effective conversion price embedded
in this note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company accounts for the conversion of convertible debt when a conversion
option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying
amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment
of the two separate accounting liabilities.</p>


<ix:exclude><!-- Field: Page; Sequence: 37 -->
    <div id="xdx_23C_zLpqQjd4YMed" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_239_z4r9LPkwyFh9" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23C_zKff9qGSnwT5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><p id="xdx_23C_zERTzQUy02sa" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_231_ztnITDX7BUTk" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zHCz9ginFYI5" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zlwZSWFXGGI2" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>


<ix:exclude><p id="xdx_238_z0AnmszMTIre" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_zHnAQmNImCt3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><span style="font-style: normal">&nbsp;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zvjOeK8B0fSj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Convertible Instruments (continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zxXkSLmg9sVf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><i>&nbsp;</i></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>See Note 9,</i> “Derivative Financial Instruments” for disclosures
regarding the derivative embedded in the 7% Convertible Debentures issued by the Company in November 2020 and exchanged for Common Stock
on May 6, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp; &nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" inside-table="false" id="fact-identifier-266" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84A_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z7lFFhLiOFGl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_868_z5KuRt6XaV08">Share-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company follows the provisions of FASB ASC 718 requiring employee equity
awards to be accounted for under the fair value method. Accordingly, share-based compensation is measured at grant date, based on the
fair value of the award and recognized over its vesting period. No equity instruments were granted to employees during the year ending
December 31, 2021 and no compensation expense is required to be recognized under provisions of ASC 718 with respect to employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" inside-table="false" id="fact-identifier-267" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84D_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zJF5pnXBCg23" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_869_zIq6xwLG5Zb3">Fair Value of Financial Instruments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company follows ASC 825-10-50-10 with respect to disclosures about
fair value of its financial instruments and ASC 820-10-35-37 to measure the fair value of its financial instruments. ASC 820-10-35-37
establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America, and expands
disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures,
ASC 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into
three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical
assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph
820-10-35-37 are described below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 1: Quoted market prices available in active markets for identical
assets or liabilities as of the reporting date.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 2: Pricing inputs other than quoted prices in active markets included
in Level 1, which are either directly or indirectly observable as of the reporting date.</span></td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 10pt"><tbody><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Symbol; font-size: 10pt">·</span></td><td style="text-align: justify"><span style="font-size: 10pt">Level 3: Pricing inputs that are generally unobservable inputs and not corroborated
by market data.</span></td></tr></tbody></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Determining which category an asset or liability falls within the hierarchy
requires significant judgment. The Company evaluates its hierarchy disclosures each quarter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Financial assets and liabilities of the Company primarily consist of cash,
prepaid expenses, accounts payable and accrued liabilities, other payables and convertible debentures. As of December 31, 2021, the carrying
values of these financial instruments (other than convertible debentures) approximated their fair values due to the short-term nature
of these instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>See</i>: Note 9, "Derivative Financial Instruments", for fair
value disclosures regarding the convertible debentures issued by the Company in November 2020 and exchanged for Common Stock on May 6,
2021. The derivative liability is classified as a Level 3 liability, and is the only financial liability measure at fair value on a recurring
basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">There were no transfers between level 1, level 2 or level 3 measurements
during the year ending December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp; &nbsp;</p>


<ix:exclude><!-- Field: Page; Sequence: 38 -->
    <div id="xdx_233_z6j8nfSoEuef" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_234_zv2de8ViC29g" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23F_zoeQCNRMOhYg" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zZzm3Njle6E5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><p id="xdx_233_zPvlIon4Z8B5" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z3smmPxeoKu6" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_238_z0CGsGqsGsIc" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zJAksC4yW6S6" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>


<ix:exclude><p id="xdx_239_z5pTq6c1BZl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zy5mpITfbHuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-268" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zgjv0WRT4s75" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_861_z3NzXkVhTZm3">Earnings Per Share</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company calculates earnings per share (“EPS”) as required
by ASC 260, Earnings Per Share. Basic EPS is calculated by dividing the net income available to common stockholders by the weighted average
number of common shares outstanding for the period, excluding common stock equivalents. Diluted EPS is computed by dividing the net income
available to common stockholders by the weighted average number of common shares outstanding for the period, plus the weighted average
number of dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. For periods with a
net loss, the dilutive common stock equivalents are excluded from the diluted EPS calculation. For purposes of this calculation, common
stock subject to repurchase by the Company, options, and warrants are considered to be common stock equivalents and are only included
in the calculation of diluted earnings per share when their effect is dilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-269" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_84F_eus-gaap--IncomeTaxPolicyTextBlock_zuRRCPOVPf53" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_861_zXTHJEoJvr91">Income Taxes</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company follows ASC Topic 740, Income Taxes, which requires the recognition
of deferred income taxes for the differences between the basis of assets and liabilities for financial statements and income tax purposes.
Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases
of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable
to the periods in which the differences are expected to affect taxable income. Deferred tax assets are also recognized for operating losses
and for tax credit carryforwards. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected
to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">ASC 740-10-30 requires income tax positions to meet a more-likely-than-not
recognition threshold to be recognized in the financial statements. Under ASC 740-10-30, tax positions that previously failed to meet
the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is
met. Under ASC 740-10-40, previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized
in the first subsequent financial reporting period in which that threshold is no longer met. The Company had no material uncertain tax
positions as of December 31, 2021 or December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The application of tax laws and regulations is subject to legal and factual
interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy,
changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from
our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities
or the deferred tax asset valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp; &nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-270" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zeDfc8OZ5s6f" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="xdx_86A_zwuYuvdFukZ5">Recently Adopted Accounting Standards</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has reviewed recently issued accounting pronouncements and
plans to adopt those that are applicable to it. The Company does not expect the adoption of any recently issued pronouncements to have
an impact on its results of operations or financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-271" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zt52F8TFNzHg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 3 – <span id="xdx_827_zy5FpsEsP903">GOING CONCERN</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The accompanying financial statements have been prepared on a going concern
basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company
has not generated any revenue since inception, and has an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20211231_zjmPLjK9Nyg5" title="Accumulated deficit"><span><ix:nonfraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="false" id="fact-identifier-272" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,547,924</ix:nonfraction></span></span> as of December 31, 2021. These conditions,
among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not
include any adjustments that may result from the outcome of these uncertainties. The financial statements do not include any adjustments
to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities
that may result from the possible inability of the Company to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Management anticipates that the Company will be dependent, for the near
future, on additional investment capital or debt to fund operating expenses until its planned operations generate sufficient revenue to
offset the Company’s expenses. Management, therefore, is actively pursuing sources of investment capital.</p>


<ix:exclude><!-- Field: Page; Sequence: 39 -->
    <div id="xdx_230_zp6arGxXMcL9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td id="xdx_239_zbAH93NU17Nh" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_230_z92XbEtZnLij" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zxXjihLjBSb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><p id="xdx_230_zLP4Nc0Uxi8k" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zEYCciRCYDSk" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zuEIS5VnYxI2" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_z2R9W00K6r5i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IntangibleAssetsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-273" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_807_eus-gaap--IntangibleAssetsDisclosureTextBlock_zocOy3cp24G8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 4 – <span id="xdx_825_zO837z2dQVPc">INTANGIBLE ASSETS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company’s intangible assets consist of the intellectual property
relating to medical imaging contributed to Medi-Scan in 2018 as a capital contribution. The intangible assets were amortized over three
years. Amortization expense relating to the intangible assets totaled $<span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20211231_pp0p0" title="Amortization expense"><span><ix:nonfraction name="us-gaap:AmortizationOfIntangibleAssets" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,926</ix:nonfraction></span></span> in the year ended December 31, 2021, and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20201231_pp0p0" title="Amortization expense"><span><ix:nonfraction name="us-gaap:AmortizationOfIntangibleAssets" contextref="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-275" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38,889</ix:nonfraction></span></span> in the
year ended December 31, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="hltt:DiscontinuedOperationsInvestmentAdvanceNonConsolidatedSubsidiaryTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-276" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><p id="xdx_805_ecustom--DiscontinuedOperationsInvestmentAdvanceNonConsolidatedSubsidiaryTextBlock_zYI2qow2pmQ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5 - <span id="xdx_822_zkfJjRfIwfX4">DISCONTINUED OPERATIONS; INVESTMENT IN AND ADVANCE TO NON-CONSOLIDATED
SUBSIDIARY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 7, 2021 the Company acquired ownership of Varian Biopharmaceuticals,
Inc. (“Varian”) from its original shareholders (the “Varian Shareholders”) in exchange for <span id="xdx_904_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_pp0d_c20210501__20210507__us-gaap--BusinessAcquisitionAxis__custom--HealthtechSolutionsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCPreferredStocksMember_zU8TkkWNdjj" title="Business acquisition exchange of shares"><span><ix:nonfraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextref="From2021-05-012021-05-07_custom_HealthtechSolutionsMember_custom_SeriesCPreferredStocksMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-277" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,737</ix:nonfraction></span></span>.184 shares of
Series C Preferred Stock issued by Healthtech Solutions. The Company determined that the fair value of the Series C Preferred Stock was
equal to the amount of cash acquired in the transaction plus the amount of debt in excess of that cash that was assumed, and allocated
the fair value accordingly between the assets acquired and the liabilities assumed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The parties subsequently agreed that the relationship between Healthtech
Solutions and Varian was not achieving its intended results. Therefore, on November 9, 2021, the Company entered into a Share Exchange
Agreement (the "SEA") with the Varian Shareholders. in order to unwind its acquisition of Varian. Pursuant to the SEA, (a) the
Varian Shareholders returned to Healthtech all of the outstanding shares of Healthtech Series C Preferred Stock and (b) Healthtech caused
all of the outstanding shares of Varian common stock to be returned to the Varian Shareholders. Immediate subsequently, Varian issued
to Healthtech Varian shares that represent 5.5% of the outstanding shares of Varian.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has valued its 5.5% interest in Varian at $<span id="xdx_900_ecustom--FairMarketValue_iI_c20211231__us-gaap--BusinessAcquisitionAxis__custom--VarianBiopharmaceuticalIncMember_zjkbD3rFCDj2" title="Fair market value"><span><ix:nonfraction name="hltt:FairMarketValue" contextref="AsOf2021-12-31_custom_VarianBiopharmaceuticalIncMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-278" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60,000</ix:nonfraction></span></span>, which represents
5.5% of the fair market value of Varian. That asset has been combined on the Company’s balance sheet with a $<span id="xdx_90B_eus-gaap--ReceivablesNetCurrent_iI_c20211231__us-gaap--BusinessAcquisitionAxis__custom--VarianBiopharmaceuticalIncMember_z5SyrGMIACS" title="Receivable"><span><ix:nonfraction name="us-gaap:ReceivablesNetCurrent" contextref="AsOf2021-12-31_custom_VarianBiopharmaceuticalIncMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-279" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,000</ix:nonfraction></span></span> receivable from
Varian provided for in the SEA, and the combination is classified as “investment in and advance to non-consolidated affiliate”</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Varian incurred $<span id="xdx_908_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_c20210501__20210507__us-gaap--BusinessAcquisitionAxis__custom--VarianBiopharmaceuticalIncMember_zKvFtGuXlf9g" title="Loss from discontinued operations"><span><ix:nonfraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextref="From2021-05-012021-05-07_custom_VarianBiopharmaceuticalIncMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-280" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">668,960</ix:nonfraction></span></span> in operating loss from the date of acquisition
5/7/2021 through the date of disposition 11/9/2021. That loss has been recorded on the Company’s Statements of Operations as a Loss
from Discontinued Operations, Net of Taxes.In addition to the operating loss from discontinued operations, HLTT incurred a $<span id="xdx_90D_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_c20211101__20211109__us-gaap--BusinessAcquisitionAxis__custom--HealthcareSolutionIncMember_zw6AI71rixXd" title="Loss from discontinued operations"><span><ix:nonfraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextref="From2021-11-012021-11-09_custom_HealthcareSolutionIncMember" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-281" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,111</ix:nonfraction></span></span> Loss
from Disposal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the provisional fair values of the assets
acquired and liabilities assumed on May 7, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>ACQUISITION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-282" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_zwAMzDMUdZ8h" summary="xdx: Disclosure -  DISCONTINUED OPERATIONS INVESTMENT IN AND ADVANCE TO NON-CONSOLIDATED SUBSIDIARY (Details)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold"><span id="xdx_8B3_zc3zMRjt7nQl" style="display: none">Schedule of Acquisition</span></td><td>&nbsp;</td>
    <td colspan="3" id="xdx_492_20210507" style="text-align: center">&nbsp;</td></tr>
<tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_iB" style="vertical-align: bottom">
    <td style="font-size: 10pt; font-weight: bold">Assets acquired:</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-indent: 0.2in">Cash</td><td style="width: 10%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 18%; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextref="AsOf2021-05-07" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-283" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,658</ix:nonfraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt; text-indent: 0.2in">Goodwill</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" contextref="AsOf2021-05-07" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,104,388</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_i01I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0.4in">Total assets acquired</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextref="AsOf2021-05-07" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-285" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,106,046</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left">Liabilities assumed:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_i02I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; text-indent: 0.2in">Accounts payable</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextref="AsOf2021-05-07" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-286" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,372</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; text-indent: 0.2in">Accrued expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="hltt:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses" contextref="AsOf2021-05-07" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-287" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">370,594</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_i02I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 0.2in">Loans payable</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" contextref="AsOf2021-05-07" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-288" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">725,080</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_i02I_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: 0.4in">Total liabilities assumed</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" contextref="AsOf2021-05-07" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-289" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,106,046</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A5_zswqAAxtGgo2" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;The following table sets forth the components of the loss from discontinued
operations realized by the Company during the year ended December 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="hltt:ScheduleOfLossFromDiscontinuedOperationsTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-290" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ScheduleOfLossFromDiscontinuedOperationsTableTextBlock_zZL2zeZ3OGFa" summary="xdx: Disclosure -  Disclosure -  DISCONTINUED OPERATIONS INVESTMENT IN AND ADVANCE TO NON-CONSOLIDATED SUBSIDIARY (Details 1)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B6_zogBte2Vdsp2" style="display: none">Schedule of loss from discontinued operations</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_492_20210101__20211231_z2ZHl2Ln2fY" style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">May 7, 2021 –</span></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 10pt">Nov. 8, 2021</span></p></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_zqT7K5UU25Ke" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; padding-bottom: 1pt">Revenue</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560"><span><ix:nonfraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" contextref="From2021-01-01to2021-12-31" id="fact-identifier-291" unitref="USD" xs:nil="true" isadditionalitemsonly="true" ishiddenelement="true" inside-table="true" data-original-id="xdx2ixbrl0560" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Operating Expenses:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_zNZtCc1sgDCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left">General &amp; Administrative</td><td style="width: 10%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 18%; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-292" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">463,026</ix:nonfraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_ecustom--DisposalGroupIncludingDiscontinuedOperationResearchDevelopment_zfCOc4b1bRQh" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Research &amp; Development</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span><ix:nonfraction name="hltt:DisposalGroupIncludingDiscontinuedOperationResearchDevelopment" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-293" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">205,934</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_zqgPGx66i0je" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total Operating Expenses</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="true" id="fact-identifier-294" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">668,960</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_pp0p0_zyw3SYondNSk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Loss before provision for income tax</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">(<span><ix:nonfraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-295" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">668,960</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--GainLossOnDispositionOfAssets1_pp0p0_zvvc2PzEqXXf" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Loss on disposal</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<span><ix:nonfraction name="us-gaap:GainLossOnDispositionOfAssets1" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-296" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,111</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--IncomeLossFromDiscontinuedOperationNetOfTax_pp0p0_zRmrBu6ANCg9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left">Total loss on discontinued operations that is presented in the Statement of Operations</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">(<span><ix:nonfraction name="hltt:IncomeLossFromDiscontinuedOperationNetOfTax" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitref="USD" inside-table="true" id="fact-identifier-297" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">803,071</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
  </tbody></table>


</ix:nonnumeric></span><p id="xdx_8AA_z9TDFkIF5DHk" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<ix:exclude><!-- Field: Page; Sequence: 40 -->
    <div id="xdx_233_z4h5QSJAslOg" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td id="xdx_23A_zUT5dXqQZqsb" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_23D_zXCNO7NIl0cb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&nbsp;HEALTHECH SOLUTIONS,
INC.</b></span></p>

<ix:exclude><p id="xdx_236_z0ex3ApCZCDj" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zY9V2d2pL0U8" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>


<ix:exclude><p id="xdx_239_zdgBgMTZWYfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p></ix:exclude>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-298" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_803_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zMCdCqoeRR17" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6 – <span id="xdx_820_zT6Xsfo4C91i">RELATED PARTIES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the first five months of 2020, Medi-Scan paid $<span id="xdx_90D_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c20200801__20201231__us-gaap--RelatedPartyTransactionAxis__custom--DenisKleinfeldMember_pp0p0" title="Related party transacation monthly expenses"><span><ix:nonfraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextref="From2020-08-012020-12-31_custom_DenisKleinfeldMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-299" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000</ix:nonfraction></span></span> per month
to a law firm owned by Denis Kleinfeld, who was a managing member of Medi-Scan at that time and became a member of the Board of Directors
of Healthtech Solutions in September 2020. The payment included $<span id="xdx_90C_eus-gaap--OfficersCompensation_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--DenisKleinfeldMember_pp0p0" title="Compensation payment for law firm"><span><ix:nonfraction name="us-gaap:OfficersCompensation" contextref="From2021-01-012021-12-31_custom_DenisKleinfeldMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,447</ix:nonfraction></span></span> as compensation for use of the law firm's offices as the executive
offices of Medi-Scan, the remainder was compensation for the administrative and other services of employees of the law firm, and for legal
services by Mr. Kleinfeld.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">For legal services rendered as counsel to Healthtech Solutions during the
period January 1, 2021 to December 31, 2021, Healthtech Solutions recorded $<span id="xdx_904_eus-gaap--LegalFees_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--RobertBrantllMember_pp0p0" title="Legal Services"><span><ix:nonfraction name="us-gaap:LegalFees" contextref="From2021-01-012021-12-31_custom_RobertBrantllMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-301" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245,132</ix:nonfraction></span></span> in fees and expenses payable to Robert Brantl. Mr.
Brantl was the sole officer and director of Healthtech Solutions until September 4, 2020 and has served as Secretary of Healthtech Solutions
since September 4, 2020. Healthtech Solutions no longer considers Mr. Brantl to be a related party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In May 2020 David Rubin, through his personal holding company, Storm Funding
LLC, agreed to contribute $<span id="xdx_908_eus-gaap--ProceedsFromContributionsFromParent_c20210101__20211231__srt--TitleOfIndividualAxis__custom--StormFundingLLCMember__us-gaap--AwardDateAxis__custom--MayTwoThousandTwentyMember__us-gaap--RelatedPartyTransactionAxis__custom--DavidRubinMember_pp0p0" title="Proceeds from realted party contribution"><span><ix:nonfraction name="us-gaap:ProceedsFromContributionsFromParent" contextref="From2021-01-012021-12-31_custom_StormFundingLLCMember_custom_MayTwoThousandTwentyMember_custom_DavidRubinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-302" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">250,000</ix:nonfraction></span></span> to Medi-Scan in exchange for a 25% equity interest in Medi-Scan. During the remainder of 2020, Mr.
Rubin satisfied $<span id="xdx_909_eus-gaap--DefinedBenefitPlanSettlementsBenefitObligation_c20210101__20211231__us-gaap--AwardDateAxis__custom--MayTwoThousandTwentyMember__us-gaap--RelatedPartyTransactionAxis__custom--MrRubinMember_pp0p0" title="Settlement of obligation"><span><ix:nonfraction name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextref="From2021-01-012021-12-31_custom_MayTwoThousandTwentyMember_custom_MrRubinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245,442</ix:nonfraction></span></span> of the obligation: he contributed $<span id="xdx_901_ecustom--ContributedObligationToPay_c20210101__20211231__srt--TitleOfIndividualAxis__custom--StormFundingLLCMember__us-gaap--AwardDateAxis__custom--MayTwoThousandTwentyMember__us-gaap--RelatedPartyTransactionAxis__custom--DavidRubinMember_pp0p0" title="Contributed obligation to pay"><span><ix:nonfraction name="hltt:ContributedObligationToPay" contextref="From2021-01-012021-12-31_custom_StormFundingLLCMember_custom_MayTwoThousandTwentyMember_custom_DavidRubinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">142,761</ix:nonfraction></span></span> by paying obligations incurred by Medi-Scan in that amount, and Mr.
Rubin satisfied a total of $<span id="xdx_90E_ecustom--TotalObligationToPay_c20210101__20211231__us-gaap--AwardDateAxis__custom--MayTwoThousandTwentyMember__us-gaap--RelatedPartyTransactionAxis__custom--MrRubinMember_pp0p0" title="Total obligation to pay"><span><ix:nonfraction name="hltt:TotalObligationToPay" contextref="From2021-01-012021-12-31_custom_MayTwoThousandTwentyMember_custom_MrRubinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-305" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">102,681</ix:nonfraction></span></span> <span id="xdx_906_ecustom--DescriptionOfServicesAndAdministrativeObligation_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--EProdigyFinancialLLCMember__us-gaap--RelatedPartyTransactionAxis__custom--MrRubinMember" title="Description of services and administrative obligation"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_custom_EProdigyFinancialLLCMember_custom_MrRubinMember" name="hltt:DescriptionOfServicesAndAdministrativeObligation" inside-table="false" id="fact-identifier-306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">of the obligation by contributing to Medi-Scan the services of administrative personnel employed by
Storm Funding LLC, a company owned by Mr. Rubin. During the period from January 1, 2021 to December 31, 2021 Mr Rubin satisfied the remainder
of his contribution of $<span id="xdx_90C_eus-gaap--ProceedsFromContributionsFromParent_c20210101__20211231_pp0p0" title="Proceeds from realted party contribution"><span><ix:nonfraction name="us-gaap:ProceedsFromContributionsFromParent" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-307" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,558</ix:nonfraction></span></span>.</ix:nonnumeric></span></span> During that period, &nbsp;Mr Rubin also loaned $<span id="xdx_90C_eus-gaap--RevenueFromRelatedParties_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--EProdigyFinancialLLCMember__us-gaap--RelatedPartyTransactionAxis__custom--MrRubinMember_pp0p0" title="Related party debt"><span><ix:nonfraction name="us-gaap:RevenueFromRelatedParties" contextref="From2021-01-012021-12-31_custom_EProdigyFinancialLLCMember_custom_MrRubinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-308" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107,000</ix:nonfraction></span></span> to the Company and contributed services of Storm
Funding LLC valued at $<span id="xdx_90D_ecustom--ContributedServicesValue_c20210101__20211231__us-gaap--FinancialInstrumentAxis__custom--EProdigyFinancialLLCMember__us-gaap--RelatedPartyTransactionAxis__custom--MrRubinMember_pp0p0" title="Contributed services value"><span><ix:nonfraction name="hltt:ContributedServicesValue" contextref="From2021-01-012021-12-31_custom_EProdigyFinancialLLCMember_custom_MrRubinMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-309" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">52,464</ix:nonfraction></span></span>, which is included in Loans from Shareholders on the Company's Balance Sheets. Mr. Rubin was a managing member of Medi-Scan commencing in May 2020 and served as Chairman and CEO of Healthtech
Solutions from September 2020 through July 19, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp; &nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 4, 2021 the Company entered into an Advisory Agreement with Kleinfeld
Legal Services P.A., which is owned by Denis Kleinfeld. Mr. Kleinfeld was, until April 24, 2021, a member of the Company's Board of Directors.
Pursuant to the Advisory Agreement, Kleinfeld Legal Services P.A. will provide legal and advisory services to Medi-Scan Inc. during the
next two years. In consideration of the services, the Company will pay Kleinfeld Legal Services a $<span id="xdx_903_ecustom--LegalServiceSigningFee_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--DenisKleinfeldMember__us-gaap--StatementBusinessSegmentsAxis__custom--AdvisoryAgreementMember_pp0p0" title="Legal service signing fee"><span><ix:nonfraction name="hltt:LegalServiceSigningFee" contextref="From2021-01-012021-12-31_custom_DenisKleinfeldMember_custom_AdvisoryAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100,000</ix:nonfraction></span></span> signing fee plus a services
fee of $<span id="xdx_903_ecustom--ServiceFee_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--DenisKleinfeldMember__us-gaap--StatementBusinessSegmentsAxis__custom--AdvisoryAgreementMember_pp0p0" title="Service fee"><span><ix:nonfraction name="hltt:ServiceFee" contextref="From2021-01-012021-12-31_custom_DenisKleinfeldMember_custom_AdvisoryAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-311" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">150,000</ix:nonfraction></span></span> per year. The Company also assigned to Kleinfeld Legal Services 19.9% of the capital stock of Medi-Scan, Inc.&nbsp;&nbsp;During
the year ended December 31, 2021, the company recorded expenses for advisory services from Kleinfeld Legal Services totaling $<span id="xdx_903_eus-gaap--LegalFees_c20210101__20211231__us-gaap--RelatedPartyTransactionAxis__custom--DenisKleinfeldMember__us-gaap--StatementBusinessSegmentsAxis__custom--AdvisoryAgreementMember_pp0p0" title="Legal Services"><span><ix:nonfraction name="us-gaap:LegalFees" contextref="From2021-01-012021-12-31_custom_DenisKleinfeldMember_custom_AdvisoryAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-312" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200,000</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 10, 2021, in compensation for services, the Company issued
<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pn3n3_dm_c20211101__20211110_z16MPZQSrxq5" title="Shares issued for services"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2021-11-012021-11-10" format="ixt:numdotdecimal" decimals="-3" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-313" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.5</ix:nonfraction></span></span> million shares of common stock to each of the non-executive members of its Board of Directors and <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pn3n3_dm_c20211101__20211110__srt--TitleOfIndividualAxis__custom--GeneralCounselMember_zC2S0zJ3rNsd"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2021-11-012021-11-10_custom_GeneralCounselMember" format="ixt:numdotdecimal" decimals="-3" scale="6" unitref="Shares" inside-table="false" id="fact-identifier-314" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span></span> million shares of common stock
to its General Counsel. The market price of the common stock on the date of grant was $<span id="xdx_905_eus-gaap--SharePrice_iI_c20211110_zYMVZimIIoyh" title="Share price"><span><ix:nonfraction name="us-gaap:SharePrice" contextref="AsOf2021-11-10" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-315" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">.55</ix:nonfraction></span></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During 2021, the Company borrowed $<span id="xdx_90D_eus-gaap--OtherBorrowings_iI_c20211231_zzHyjE9Cliie" title="Borrowings"><span><ix:nonfraction name="us-gaap:OtherBorrowings" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-316" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336,921</ix:nonfraction></span></span> from a number of its shareholders.
The loans are unsecured, payable on demand and bear interest at <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_dp_c20211231_zhGlBKxu1Tc8" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-317" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7</ix:nonfraction></span></span>% per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zLiXewRxc4Y2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 – <span id="xdx_828_zOg88m7oI6u2">SHAREHOLDERS EQUITY</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Authorized Capital Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table sets forth information, as of December 31, 2021, regarding
the classes of capital stock that are authorized by the Articles of Incorporation of Healthtech Solutions, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfStockholdersEquityTableTextBlock_zFPuXWet7Y79" summary="xdx: Disclosure - SHAREHOLDERS EQUITY (Details)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left"><span id="xdx_8B6_zF5TtF77adk2" style="display: none">Summary of Shareholders Equity</span></td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right">&nbsp;</td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt">Class</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Shares Authorized</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">Shares Outstanding</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-size: 10pt">Common Stock, $.001 par value</td><td style="width: 8%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td id="xdx_989_ecustom--SharesAuthorized_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_pdd" title="Shares Authorized" style="width: 12%; font-size: 10pt; text-align: right"><span><ix:nonfraction name="hltt:SharesAuthorized" contextref="AsOf2021-12-31_custom_CommonStockOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-320" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">200,000,000</ix:nonfraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 8%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_c20211231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_pdd" title="Shares Outstanding" style="width: 12%; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_custom_CommonStockOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-321" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,965,933</ix:nonfraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Series A Preferred Stock, $.001 par value</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td id="xdx_98C_ecustom--SharesAuthorized_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAPreferredStockOneMember_pdd" title="Shares Authorized" style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="hltt:SharesAuthorized" contextref="AsOf2021-12-31_custom_SeriesAPreferredStockOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-322" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">156,937</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td id="xdx_980_eus-gaap--SharesOutstanding_c20211231__us-gaap--StatementClassOfStockAxis__custom--SeriesAPreferredStockOneMember_pdd" title="Shares Outstanding" style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_custom_SeriesAPreferredStockOneMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-323" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">110,520</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt">Undesignated Preferred Stock, $.001 par value</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td id="xdx_980_ecustom--SharesAuthorized_c20211231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_pdd" title="Shares Authorized" style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="hltt:SharesAuthorized" contextref="AsOf2021-12-31_custom_UndesignatedPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-324" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,843,163</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td id="xdx_985_eus-gaap--SharesOutstanding_c20211231__us-gaap--StatementClassOfStockAxis__custom--UndesignatedPreferredStockMember_pdd" title="Shares Outstanding" style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:SharesOutstanding" contextref="AsOf2021-12-31_custom_UndesignatedPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="true" id="fact-identifier-325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp; &nbsp;</p>


<ix:exclude><!-- Field: Page; Sequence: 41 -->
    <div id="xdx_23A_zgE42OcdWzT7" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td id="xdx_234_zyn08yYchvr1" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_232_zwb4YKe8nYze" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><p id="xdx_23C_zYwUXFbInuEh" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_230_zM7qhZMs49S5" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_236_zbWDrLIpVhL6" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zkJ1xXpGOsWd" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>


<ix:exclude><p id="xdx_23D_zFruIxY9wpR7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 7 – SHAREHOLDERS EQUITY (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zpdSOORiA88k" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i>Series A Preferred Stock.</i> The Series A
Preferred Stock was authorized on November 16, 2020. <span id="xdx_902_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember" name="us-gaap:ConvertiblePreferredStockTermsOfConversion" inside-table="false" id="fact-identifier-326" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">When first authorized, each
share of Series A Preferred Stock was convertible by the holderat any time into two thousand (2.00) shares of Common Stock
and had voting rights equivalent to the voting rights of 2,000 shares of common stock.</ix:nonnumeric></span></span> On November 12, 2021, after a vote of the
Board of Directors, the Company's shareholders and the holders of the outstanding Series A Preferred Stock voting as a class,
Articles of Amendment of the Company's Articles of Incorporation were filed which modified the terms of the Series A Preferred
Stock such that each share of Series A Preferred Stock is now convertible by the holder into fifty (50 shares of Common Stock
at any time after May 31, 2024. and<span id="xdx_909_eus-gaap--PreferredStockVotingRights_c20210101__20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember" title="Preferred stock voting rights"> <span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_SeriesAPreferredStockMember" name="us-gaap:PreferredStockVotingRights" inside-table="false" id="fact-identifier-327" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">entitles a stockholder to voting rights equivalent to those of 50 shares of Common Stock on all
matters upon which stockholders are permitted to vote.</ix:nonnumeric></span></span> In the event of our liquidation, dissolution or winding up, after
payment of all creditors, holders of our Series A Preferred Stock are entitled to receive, ratably, a preferential payment of $.01
per share, then to share pro rate in the net assets available to stockholders on an as-converted basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i>Undesignated
Preferred Stock.</i> The Board of Directors has authority, without shareholder approval and by resolution of the Board of Directors, to
amend the Corporation's Articles of Incorporation to divide the class of undesignated Preferred Stock into series, to designate each such
series by a distinguishing letter, number or title so as to distinguish the shares thereof from the shares of all other series and classes,
and to fix and determine the following relative rights and preferences of the shares of each series so established.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Exchange of Series A Preferred Stock for Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 14, 2021 the Company entered into an Exchange Agreement with Richard
Parker, who is Medi-Scan's Chief Research Officer. Pursuant to the Exchange Agreement, <span id="xdx_902_ecustom--CaptialContributionDescription_c20180101__20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MediScansFounderMember" title="Capital contribution description"><span><ix:nonnumeric contextref="From2018-01-012018-12-31_custom_MediScansFounderMember" name="hltt:CaptialContributionDescription" inside-table="false" id="fact-identifier-328" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">Mr. Parker's family trust exchanged 29,407 shares
of the Company's Series A Preferred Stock  for 6,000,000 shares of the Company's common stock, and the Company
assigned to Mr. Parker's family trust 18.75% of the outstanding shares of Medi-Scan, Inc.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On October 6, 2021, the holders of <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20211001__20211006_zJehnjP2YRSf" title="Conversion of shares"><span><ix:nonfraction name="us-gaap:ConversionOfStockSharesConverted1" contextref="From2021-10-012021-10-06" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-329" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,910</ix:nonfraction></span></span> shares of the Company's Series
A Preferred Stock converted those shares into <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_c20211001__20211006__us-gaap--StatementClassOfStockAxis__custom--SeriesAPreferredStocksMember_zG56OubhzBs9"><span><ix:nonfraction name="us-gaap:ConversionOfStockSharesConverted1" contextref="From2021-10-012021-10-06_custom_SeriesAPreferredStocksMember" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-330" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,820,000</ix:nonfraction></span></span> shares of the Company's common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Issuance of Common Stock for Settlement of Convertible Debentures</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 6, 2021, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210501__20210506_zkyzGgsaD7vb" title="Common stock shares issued during the period, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-05-012021-05-06" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,507,164</ix:nonfraction></span></span> shares of common shares in
exchange for the settlement of the convertible debentures, see Note 8 and Note 9.&nbsp; These shares were valued at the previous market
closing price of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_c20210506_pdd" title="Price per share"><span><ix:nonfraction name="us-gaap:SaleOfStockPricePerShare" contextref="AsOf2021-05-06" format="ixt:numdotdecimal" decimals="INF" unitref="USDPShares" inside-table="false" id="fact-identifier-332" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.14</ix:nonfraction></span></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Issuance
of Common Stock for Services</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">&nbsp;</span></i></b></span></p>

<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021,
the Company issued<span id="xdx_90B_ecustom--CommonStockForServicesShares_c20210101__20211231_z4f8usrApXna" title="Common stock for services shares"> <span><ix:nonfraction name="hltt:CommonStockForServicesShares" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitref="Shares" inside-table="false" id="fact-identifier-333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,975,000</ix:nonfraction></span></span> shares of common stock for services rendered valued at $<span id="xdx_905_ecustom--CommonStockForServicesValue_c20210101__20211231_zlurAd6GU2c9" title="Common stock for services value"><span><ix:nonfraction name="hltt:CommonStockForServicesValue" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="USD" inside-table="false" id="fact-identifier-334" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,229,028</ix:nonfraction></span></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&nbsp;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Capital Contributions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90B_ecustom--CaptialContributionDescription_c20180101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MediScansFounderMember" title="Capital contribution description"><span><ix:nonnumeric contextref="From2018-01-012020-12-31_custom_MediScansFounderMember" name="hltt:CaptialContributionDescription" inside-table="false" id="fact-identifier-335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">Medi-Scan's founders contributed $4,558 to the Company during the year
ended December 31, 2021, and $270,442 during the year ended December 31, 2020.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 21, 2020, <span id="xdx_90A_ecustom--CaptialContributionDescription_c20200501__20200531__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MediScansFounderMember" title="Capital contribution description"><span><ix:nonnumeric contextref="From2020-05-012020-05-31_custom_MediScansFounderMember" name="hltt:CaptialContributionDescription" inside-table="false" id="fact-identifier-336" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">Medi-Scan entered into agreement with Storm Funding LLC,
a company owned by David Rubin. Storm Funding LLC committed to invest $250,000 in exchange for a 25% membership interest in Medi-Scan.
At the same time, David Rubin joined Medi-Scan as Executive Chairman. The financing commitment has been fully satisfied.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In May 2021, the Company issued to 30 accredited investors <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210401__20210531_pp0d" title="Common stock shares issued during the period, shares"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextref="From2021-04-012021-05-31" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-337" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,962,500</ix:nonfraction></span></span> shares
of common stock for aggregate cash proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210401__20210531_pp0p0" title="Proceeds from issuance of share"><span><ix:nonfraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextref="From2021-04-012021-05-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,792,500</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:DebtDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-339" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zQhlCbBcZgJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 – <span id="xdx_824_zVx0LppzilQ6">EXCHANGEABLE NOTES AND CONVERTIBLE DEBENTURES</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In August and September of 2020,<span id="xdx_90A_eus-gaap--DebtInstrumentDescription_c20200801__20200930__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember" title="Exchangeable promissory note description"><span><ix:nonnumeric contextref="From2020-08-012020-09-30_us-gaap_ConvertibleNotesPayableMember" name="us-gaap:DebtInstrumentDescription" inside-table="false" id="fact-identifier-340" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Medi-Scan issued four 7% Exchangeable Promissory
Notes in the aggregate principal amount of $375,000. Principal and interest were payable on the Notes on January 31, 2021.</ix:nonnumeric></span></span> The Notes provided
that, in the event that Medi-Scan was acquired by a corporation whose common stock was registered with the SEC, the Notes would be automatically
exchanged for 7% convertible debentures issued by that acquirer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<ix:exclude><!-- Field: Page; Sequence: 42 -->
    <div id="xdx_231_z9l9gHOYxEO9" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td id="xdx_23F_z3z45KXiHEu2" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_233_zNt8amHdT0M7" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_239_zfBUS5QMEK8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><p id="xdx_23E_zM9qeqLbClpf" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zgeR9sE9SZr2" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_232_z57VHZhpcISj" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zJrzTWrlQc1h" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>


<ix:exclude><p id="xdx_235_zj12xovuJ1yb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 8 – EXCHANGEABLE NOTES AND CONVERTIBLE DEBENTURES (Continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zBGAT2sOaQa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In November of 2020, <span id="xdx_900_eus-gaap--DebtInstrumentDescription_c20201101__20201130__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember" title="Exchangeable promissory note description"><span><ix:nonnumeric contextref="From2020-11-012020-11-30_us-gaap_ConvertibleNotesPayableMember" name="us-gaap:DebtInstrumentDescription" inside-table="false" id="fact-identifier-341" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">by reason of the Share Exchange, the four 7% Exchangeable
Promissory Notes were automatically exchanged for 7% Convertible Debentures issued by Healthtech Solutions in a principal amount of $381,505,
which was equal to the principal of and accrued interest on the Notes. Then, during December of 2020, Healthtech Solutions issued four
additional 7% Convertible Debentures in the aggregate principal amount of $250,000 in exchange for payment of cash in that amount. On
February 4, 2021 an additional debenture was issued in the amount $50,000.</ix:nonnumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_90E_eus-gaap--CommonStockConversionFeatures_c20210330__20210331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementClassOfStockAxis__custom--CommonSharesMember" title="Convertible debenture conversion term"><span><ix:nonnumeric contextref="From2021-03-302021-03-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember" name="us-gaap:CommonStockConversionFeatures" inside-table="false" id="fact-identifier-342" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The 7% Convertible Debentures were convertible into common stock, at the
holders’ option, at a 30% discount to the market price of the Company’s common stock. The Company determined that the conversion
feature represented a derivative financial instrument embedded in the Debentures. The accounting treatment of derivative financial instruments
requires that the Company record the fair value of that derivative financial instrument as a discount to the value of the Debentures as
of the inception date of each Debenture.</ix:nonnumeric></span></span> Accordingly, the Company recorded an aggregate initial discount of $<span id="xdx_90C_eus-gaap--LiabilitiesAssumed1_c20210330__20210331__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementClassOfStockAxis__custom--CommonSharesMember_pp0p0" title="Fair value of derivative liability"><span><ix:nonfraction name="us-gaap:LiabilitiesAssumed1" contextref="From2021-03-302021-03-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-343" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">349,202</ix:nonfraction></span></span> for the fair value
of the derivative liability at inception of each convertible debenture. During the year ending December 31, 2021, the Company amortized
$<span id="xdx_909_ecustom--AmortizedInterestExpense_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementClassOfStockAxis__custom--CommonSharesMember_pp0p0" title="Amortized Interest expense"><span><ix:nonfraction name="hltt:AmortizedInterestExpense" contextref="From2021-01-012021-12-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-344" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">27,303</ix:nonfraction></span></span> and $<span id="xdx_90A_eus-gaap--InterestExpense_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementClassOfStockAxis__custom--CommonSharesMember_pp0p0" title="Interest expenses"><span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2021-01-012021-12-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-345" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">351,202</ix:nonfraction></span></span> as interest expense. During the year ended December 31, 2020, the Company amortized $<span id="xdx_90C_eus-gaap--InterestExpense_c20200101__20201231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementClassOfStockAxis__custom--CommonSharesMember_pp0p0" title="Interest expenses"><span><ix:nonfraction name="us-gaap:InterestExpense" contextref="From2020-01-012020-12-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-346" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,277</ix:nonfraction></span></span>&nbsp;&nbsp;as interest
expense. At December 31, 2020 the notes were presented on the balance sheet, net of unamortized discount, at $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscount_c20201231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember__us-gaap--StatementClassOfStockAxis__custom--CommonSharesMember_pp0p0" title="Debt instrument Unamortized discount"><span><ix:nonfraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextref="AsOf2020-12-31_us-gaap_ConvertibleNotesPayableMember_custom_CommonSharesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">325,824</ix:nonfraction></span></span><b>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 6, 2021, by agreement with the holders of the 7% Convertible Debentures,
the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pp0d_c20210101__20211231_zAooUrjRH473" title="Issuance shares of common stock"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-348" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,507,164</ix:nonfraction></span></span> shares of common shares in exchange for surrender of the convertible debentures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp; &nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-349" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_802_eus-gaap--FinancialInstrumentsDisclosureTextBlock_zgVzIwuNiQYc" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 9 – <span id="xdx_825_z3dyo3jqLFi">DERIVATIVE FINANCIAL INSTRUMENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company determined that the conversion feature of the <span id="xdx_900_ecustom--FairValueOfEmbededFeature_dp_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_z2fA8DNah9H7" title="Fair value of embeded feature"><span><ix:nonfraction name="hltt:FairValueOfEmbededFeature" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-350" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7</ix:nonfraction></span></span>% Convertible
Debentures represented an embedded derivative since the Debentures were convertible into a variable number of shares upon conversion.
Accordingly, the Debentures are not considered to be conventional debt under ASC 815 and the embedded conversion feature was bifurcated
from the debt host and accounted for as a derivative liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The fair value of the derivatives embedded in the <span id="xdx_903_ecustom--FairValueOfEmbededFeature_dp_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zsp2HFB8FGJk" title="Fair value of embeded feature"><span><ix:nonfraction name="hltt:FairValueOfEmbededFeature" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7</ix:nonfraction></span></span>% Convertible Debentures
as of December 31, 2020 was determined using the Monte Carlo simulation method based on the following assumptions: (1) dividend yield
of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_znppmyK56IH5" title="Dividend yield"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-352" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0</ix:nonfraction></span></span>%, (2) expected volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zcycYEyiSZEi" title="Expected volatility"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-353" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">167</ix:nonfraction></span></span>%, (3) weighted average risk-free interest rate of <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zQKCUdeWosO2" title="Weighted average risk free interest rate"><span><ix:nonfraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-354" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.0</ix:nonfraction></span></span>%, (4) expected life until <span id="xdx_900_eus-gaap--DerivativeMaturityDates_dd_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zkW1ZKiCbGnc" title="Expected life"><span><ix:nonnumeric contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:datemonthdayyearen" name="us-gaap:DerivativeMaturityDates" inside-table="false" id="fact-identifier-355" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">January 31, 2024</ix:nonnumeric></span></span>,
and (5) the quoted market price of the Company’s common stock at each valuation date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At May 6, 2021, just prior to settlement, the Company marked-to-market
the fair value of the nine derivatives and determined a fair value of $<span id="xdx_907_eus-gaap--LiabilitiesAssumed1_c20210501__20210506__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Fair value of derivative liability"><span><ix:nonfraction name="us-gaap:LiabilitiesAssumed1" contextref="From2021-05-012021-05-06_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-356" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,296,997</ix:nonfraction></span></span>.&nbsp;&nbsp;The Company recorded a loss from change in
fair value of debt derivatives of $<span id="xdx_907_ecustom--ChangeInFairValueOfDerivative_c20210401__20210630__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Change in fair value of derivative"><span><ix:nonfraction name="hltt:ChangeInFairValueOfDerivative" contextref="From2021-04-012021-06-30_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-357" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,933,735</ix:nonfraction></span></span> for the year ended December 31, 2021.&nbsp;&nbsp;Upon the issuance of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0d" title="Issuance shares of common stock"><span><ix:nonfraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" unitref="Shares" inside-table="false" id="fact-identifier-358" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,507,164</ix:nonfraction></span></span> shares of
common stock (see Note 7), the balance of the derivative liability of $<span id="xdx_90F_eus-gaap--LiabilitiesAssumed1_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Fair value of derivative liability"><span><ix:nonfraction name="us-gaap:LiabilitiesAssumed1" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-359" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,296,997</ix:nonfraction></span></span> and the principal totaling $<span id="xdx_90A_ecustom--ChangeInFairValueOfDerivative_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_pp0p0" title="Change in fair value of derivative"><span><ix:nonfraction name="hltt:ChangeInFairValueOfDerivative" contextref="From2021-01-012021-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-360" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">681,581</ix:nonfraction></span></span> were reduced to $<span id="xdx_90C_ecustom--ChangeInFairValueOfDerivative_pp0p0_c20200101__20201231__us-gaap--FairValueByLiabilityClassAxis__us-gaap--DerivativeFinancialInstrumentsLiabilitiesMember_zH7H3CAnGQCg" title="Change in fair value of derivative"><span><ix:nonfraction name="hltt:ChangeInFairValueOfDerivative" contextref="From2020-01-012020-12-31_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0</ix:nonfraction></span></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">A summary of changes in derivative liabilities for the year ended December
31, 2021 was as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="hltt:SummaryOfChangesInConvertibleDebenturesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-362" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--SummaryOfChangesInConvertibleDebenturesTableTextBlock_zcKow1lVYu81" summary="xdx: Disclosure - DERIVATIVE FINANCIAL INSTRUMENTS (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B0_zH9NCQgH6wP7" style="display: none">Summary of Changes in Convertible Debentures</span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%">Balance at December 31, 2020</td><td style="width: 10%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20210101__20211231_ztLbsjvxXt8j" title="Balance at December 31, 2020" style="width: 18%; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">337,874</ix:nonfraction></span></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Issuance in February 2021</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td id="xdx_980_ecustom--IssuedDuringYear_c20210101__20211231_pp0p0" title="Issuance in February 2021" style="text-align: right"><span><ix:nonfraction name="hltt:IssuedDuringYear" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-364" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25,388</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td id="xdx_98C_ecustom--ChangeInFairValue_c20210101__20211231_pp0p0" title="Change in fair value" style="text-align: right"><span><ix:nonfraction name="hltt:ChangeInFairValue" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,933,735</ix:nonfraction></span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Settlement upon exchange for Common Stock</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td id="xdx_982_ecustom--SettlementUponExchangeForCommonStock_iN_pp0p0_di_c20210101__20211231_zyyFkajYXoVe" title="Settlement upon exchange for Common Stock" style="border-bottom: Black 1pt solid; text-align: right">(<span><ix:nonfraction name="hltt:SettlementUponExchangeForCommonStock" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-366" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,296,997</ix:nonfraction></span></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2021</td><td style="padding-bottom: 2.5pt">&nbsp;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iE_pp0p0_d0_c20210101__20211231_zatnG77JCOld" title="Balance at September 30, 2021" style="border-bottom: Black 2.5pt double; text-align: right"><span><ix:nonfraction name="us-gaap:DerivativeLiabilities" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-367" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 2.5pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></span>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<ix:exclude><!-- Field: Page; Sequence: 43 -->
    <div id="xdx_23F_zVQPwWnP0N3e" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td id="xdx_235_zmmAstt4Sjk4" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_236_zn6iTliiBL05" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_z6DWMAgBj2c8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<ix:exclude><p id="xdx_23F_zKLmzfCRfB33" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>HEALTHECH SOLUTIONS,
INC.</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_235_zIfpeEc5dMNb" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zRAkVXj3eiog" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zA2QrbCpWpVg" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>


</ix:nonnumeric></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:PremiumsReceivableNote" inside-table="false" id="fact-identifier-368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_808_eus-gaap--PremiumsReceivableNote_zrV0bBty8pYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 10 – <span id="xdx_820_zbDwnVKbTixg">NOTE RECEIVABLE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal">On December 30, 2021 the Company executed
a Term Sheet with Predictive Biotech, Inc. (“PBI”) and its parent Predictive Technology Group, Inc. (“PTG”), which
contemplated further negotiations towards the Company’s acquisition of the assets of PBI related to its wound care business. Pursuant
to the Term Sheet, the Company loaned $<span id="xdx_90D_eus-gaap--LoansReceivableHeldForSaleAmount_c20211231_pp0p0" title="Loan receivable"><span><ix:nonfraction name="us-gaap:LoansReceivableHeldForSaleAmount" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">168,000</ix:nonfraction></span></span> to PBI and PTG on that date. The loan does not bear interest. The Term Sheet provides that
the loan will be repaid by offset of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20211231_zsmEBFDqQaa4" title="Interest rate"><span><ix:nonfraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="false" id="fact-identifier-370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25</ix:nonfraction></span></span>% of royalties that may become payable to PBI from the Company’s wound care business. The
terms of that royalty arrangement were finalized in the Operations Agreement that was made by the Company, PBI, PTG and Healthtech Wound
Care Inc. in January 2022.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-weight: normal">&nbsp;</span></p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-371" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_806_eus-gaap--IncomeTaxDisclosureTextBlock_zJwmB5Svlm27" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 – <span id="xdx_823_zTAhcvcZQ189">INCOME TAX</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As discussed in Note 1, the historical financial statements presented in
this report for periods prior to November 16, 2020 are those of Medi-Scan, Inc. In prior years and through August 25, 2020, Medi-Scan,
Inc. was a limited liability company which was treated as a partnership for income tax purposes, and the tax benefit of losses realized
by the Company for that period was passed on to its members.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The provision (benefit) for income taxes consisted of the following for
2020, 2021, and for the period from the conversion of Medi-Scan to a corporation through December 31, 2020:&nbsp;&nbsp; &nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zPYPDScNdCC6" summary="xdx: Disclosure - INCOME TAX (Details)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td><span id="xdx_8B7_z8FdJcGp2YTh" style="display: none">Schedule of Provision for Income Taxes</span></td><td>&nbsp;</td>
    <td colspan="3" id="xdx_495_20210101__20211231__dei--LegalEntityAxis__custom--MediScanMember_zXZhjqT6B1za" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_49B_20210101__20211231__dei--LegalEntityAxis__custom--MediScanMember_zeppojfzzA8j" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2020</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_z74URgCHfpS4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; font-size: 10pt; text-align: left">U.S. federal statutory rate</td><td style="width: 8%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2021-01-012021-12-31_custom_MediScanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-373" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">%</td><td style="width: 8%; font-size: 10pt">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td><td style="width: 12%; font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2021-01-012021-12-31_custom_MediScanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-374" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zM9XjsMuW8Nd" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">State tax, net of federal benefit</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2021-01-012021-12-31_custom_MediScanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">%</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2021-01-012021-12-31_custom_MediScanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-376" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_ztcTVKSWGkw2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2021-01-012021-12-31_custom_MediScanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26.0</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%)</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2021-01-012021-12-31_custom_MediScanMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitref="Pure" inside-table="true" id="fact-identifier-378" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26.0</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">%)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr id="xdx_407_ecustom--NetDeferredTaxAssets_dp0_zJXbLal76c6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: 11.25pt">Net deferred tax assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span><ix:nonfraction name="hltt:NetDeferredTaxAssets" contextref="From2021-01-012021-12-31_custom_MediScanMember" format="ixt:zerodash" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span><ix:nonfraction name="hltt:NetDeferredTaxAssets" contextref="From2021-01-012021-12-31_custom_MediScanMember" format="ixt:zerodash" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-380" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A6_zDVgrZmoJqca" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="letter-spacing: -0.15pt">The following
table reconciles the effective income tax rates with the statutory rates for 2020, 2021, and for the period from the conversion date to
December 31, 2021:</span></p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-381" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zFktcKEs9FLf" summary="xdx: Disclosure - INCOME TAX (Details 1)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B4_zlVjBUBQxC44" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span>&nbsp;</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" id="xdx_49F_20210101__20211231_zh0LHsktOH4a" style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" style="text-align: center">&nbsp;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_ziSeIHZqy3Eb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; font-size: 10pt; text-align: left; padding-left: 5.4pt">U.S. federal statutory rate</td><td style="width: 10%; font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="width: 18%; font-size: 10pt; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-382" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.0</ix:nonfraction></span></td><td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_z3gIg1phsb48" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">State tax, net of federal benefit</td><td style="font-size: 10pt; font-weight: bold">&nbsp;</td>
    <td style="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-383" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.0</ix:nonfraction></span></td><td style="font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zcx5g2YJSEzd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Change in valuation allowance</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span><ix:nonfraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextref="From2021-01-01to2021-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitref="Pure" inside-table="true" id="fact-identifier-384" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">26.0</ix:nonfraction></span></td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Effective income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">—&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table>

</ix:nonnumeric></span><p id="xdx_8A0_zfuVs9SEn53f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="letter-spacing: -0.15pt">&nbsp;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Deferred tax assets are comprised of the following: &nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-385" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><table cellpadding="0" cellspacing="0" id="xdx_894_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zixfQHo5T7O3" summary="xdx: Disclosure - INCOME TAX (Details 2)" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tbody><tr style="vertical-align: bottom">
    <td><span id="xdx_8B3_zC6FCDja8vJ1" style="display: none">Schedule of Deferred Tax Assets</span></td><td>&nbsp;</td>
    <td colspan="3" id="xdx_493_20211231_z8Q2xb39b1S3" style="text-align: center">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3" id="xdx_493_20201231_zPW1orp1NHa3" style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2021</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2020</td></tr>
<tr style="vertical-align: bottom">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td><td>&nbsp;</td>
    <td colspan="3">&nbsp;</td></tr>
<tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0_maDTANzvO7_zXEG2LhfCxKa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; width: 56%"><span style="font-size: 10pt">Net operating loss carryforwards</span></td><td style="font-size: 10pt; width: 8%">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">$</td><td style="font-size: 10pt; text-align: right; width: 12%"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-386" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,109,219</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left; width: 1%"></td><td style="font-size: 10pt; width: 8%">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left; width: 1%">$</td><td style="font-size: 10pt; text-align: right; width: 12%"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsGross" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-387" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">111,265</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left; width: 1%"></td></tr>
<tr id="xdx_401_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANzvO7_zzkCTJmMbfT4" style="vertical-align: bottom; background-color: White">
    <td style="font-size: 10pt; text-align: left">Valuation allowance</td><td style="font-size: 10pt">&nbsp;</td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-388" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,109,219</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"></td>
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(<span><ix:nonfraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextref="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-389" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">111,265</ix:nonfraction></span></td><td style="font-size: 10pt; text-align: left">)</td></tr>
<tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_d0_mtDTANzvO7_zf0q5p7kngh5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Net deferred tax assets</td><td style="padding-bottom: 1pt">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2021-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; text-align: left">&nbsp;</td><td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span><ix:nonfraction name="us-gaap:DeferredTaxAssetsNet" contextref="AsOf2020-12-31" format="ixt:zerodash" decimals="0" scale="0" unitref="USD" inside-table="true" id="fact-identifier-391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;&nbsp;</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</td></tr>
</tbody></table>

</ix:nonnumeric></span><p id="xdx_8A7_zjHWUjbwypul" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At December 31, 2021, the Company had approximately $<span id="xdx_905_eus-gaap--OperatingLossCarryforwards_c20211231_pp0p0" title="Net operating loss carryforward"><span><ix:nonfraction name="us-gaap:OperatingLossCarryforwards" contextref="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitref="USD" inside-table="false" id="fact-identifier-392" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,109,219</ix:nonfraction></span></span> of
federal net operating losses (“NOL”) that may be available to offset future taxable income. <span id="xdx_90C_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_c20210101__20211231" title="Operating loss carryforward limitations on use"><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" inside-table="false" id="fact-identifier-393" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Through 2036, the amount and
utilization of any future net operating loss carry-forwards may be subject to limitations set forth by the Internal Revenue Code.</ix:nonnumeric></span></span>
Based upon an analysis of the Company’s stock ownership activity through December 31, 2021, a change of ownership was deemed
to have occurred in the 2020 fiscal year. This change of ownership created an annual limitation of substantially all of the
Company’s net operating losses which are available through 2036.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>


<ix:exclude><!-- Field: Page; Sequence: 44 -->
    <div id="xdx_234_zOVgKa2hGgnj" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td id="xdx_239_zbnztL1zaKjj" style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div id="xdx_231_zLlCvNmeCkQ6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zUvBDBMfHfx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude><p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>&nbsp;HEALTHECH
SOLUTIONS, INC.</b></span></p>

<ix:exclude><p id="xdx_23C_zVhuZqhys085" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Notes to Consolidated
Financial Statements</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_23B_zOTEI1m8iBd1" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt"><b>Years Ended December
31, 2021 and 2020</b></span></p></ix:exclude>

<ix:exclude><p id="xdx_237_zIUDFgK8Mmo2" style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 10pt">&nbsp;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23E_z6rh45tG7L6h" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 11 – INCOME TAX (continued)</b></p></ix:exclude>

<ix:exclude><p id="xdx_234_z6kI8um1J3I1" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company assesses the likelihood that deferred tax assets will be
realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company’s losses
since inception, management believes that it is more likely than not that future benefit of the deferred tax asset will not be
realized principally due to the continuing losses from operations and the change of ownership limitations and has therefore
established a full valuation allowance of all NOL’s.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The tax years ending December 31, 2020 remain open to examination by the
taxing authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

</ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="From2021-01-01to2021-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock" inside-table="false" text-block-taxonomy="true" id="fact-identifier-394" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zMvv2HYyIKi7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 12 – <span id="xdx_829_zNm4QnRpXZP9">SUBSEQUENT EVENTS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On January 31, 2022, pursuant to the Asset Purchase Agreement dated
January 18, 2022 among the Company and its newly-organized subsidiary, Healthtech Wound Care, Inc. (“HWC”), Predictive Technology
Group, Inc. (“PTG”) and its subsidiary, Predictive Biotech, Inc. (“Biotech”), HWC acquired the assets of Biotech
that were related to Biotech’s wound care business and entered into an Operations Agreement with Biotech and PTG containing terms
of their future relationship. The Company received from PTG three year options to purchase Biotech and/or Cellsure, LLC, another subsidiary
of PTG, each for a purchase price of $10. During the three year term of the options, the Company will be entitled to exercise exclusive
managerial control over the operations of Cellsure and over the operations of Biotech related to wound care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In consideration of the transfer of assets to HWC, HWC issued preferred
shares to Biotech. Until HWC achieves positive cash flow or $3.5 million in capital has been contributed to HWC, the preferred shares
held by Biotech will represent 30% of HWC’s equity and voting power. The Operations Agreement commits the Company to provide working
capital to HWC and Biotech until HWC achieves positive cash flow or the Company contributes $3.5 million or the Company determines that
market conditions make it unlikely that HWC will be financially successful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In accordance with ASC 855-10, the Company’s management has performed
subsequent events procedures through the date these financial statements were issued and determined that there are no reportable subsequent
events other than as stated above.&nbsp; &nbsp;</p>

</ix:nonnumeric></span><p id="xdx_81A_zYjeIQIpktSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: center">&nbsp;</p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><b>&nbsp;&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&nbsp;</b></p>


<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p><b>Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not Applicable.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b>Item 9A. Controls and Procedures</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>Evaluation of Disclosure Controls and
Procedures</i>. </b>As of December 31, 2021, our Principal Executive Officer and Principal Financial Officer carried out an evaluation
of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934. Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded
that our disclosure controls and procedures have the following material weaknesses:</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0 0 10pt">The Company has only one employee responsible for accounting functions, which prevents us from segregating
duties within our internal control system.</li>

<li style="margin: 0 0 10pt">The Company outsources most of its bookkeeping, accounting and financial reporting functions to employees
of a company owned by one of our shareholders. This arrangement prevents our CFO from directly supervising the Company's internal accounting
functions.</li>

<li style="margin: 0 0 10pt">We have not developed sufficient documentation concerning our existing financial processes, risk assessment
and internal controls.</li>

</ul>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Based on his evaluation, our Principal Executive
Officer and Principal Financial Officer concluded that the Company’s system of disclosure controls and procedures was not effective
as of December 31, 2021 for the purposes described in this paragraph.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><b><i>Changes in Internal Controls</i>. </b>There
was no change in internal control over financial reporting (as defined in Rule 13a-15(f) promulgated under the Securities Exchange Act
or 1934) identified in connection with the evaluation described in the preceding paragraph that occurred during Healthtech Solutions,
Inc.'s fourth fiscal quarter that has materially affected or is reasonably likely to materially affect Healthtech Solutions, Inc.'s internal
control over financial reporting.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify"><b><i>Management’s Report on Internal
Control over Financial Reporting</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Management of the Company is responsible for
establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange
Act of 1934. We have assessed the effectiveness of those internal controls as of December 31, 2021 using the Committee of Sponsoring Organizations
of the Treadway Commission (“COSO”) Internal Control – Integrated Framework (1992) as a basis for our assessment.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Because of inherent limitations, internal control
over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies
and procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even
those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</p>

<!-- Field: Page; Sequence: 46; Options: NewSection; Value: 30 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">A material weakness in internal controls is
a deficiency in internal control, or combination of control deficiencies, that adversely affects the Company’s ability to initiate,
authorize, record, process, or report external financial data reliably in accordance with accounting principles generally accepted in
the United States of America such that there is more than a remote likelihood that a material misstatement of the Company’s annual
or interim financial statements that is more than inconsequential will not be prevented or detected. In the course of making our assessment
of the effectiveness of internal controls over financial reporting, we identified three material weaknesses in our internal control over
financial reporting. These material weaknesses consisted of:</p>

<ul style="margin-top: 0in; list-style-type: disc">

<li style="margin: 0 0 10pt">There is only one employee responsible for accounting functions, which prevents us from segregating duties
within our internal control system.</li>

<li style="margin: 0 0 10pt">The Company outsources most of its bookkeeping, accounting and financial reporting functions to employees
of a company owned by one of our shareholders. This arrangement prevents our CFO from directly supervising the Company's internal accounting
functions.</li>

<li style="margin: 0 0 10pt">We have not developed sufficient documentation concerning our existing financial processes, risk assessment
and internal controls.</li>

</ul>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Management does not believe that the current
level of the Company’s operations warrants a remediation of the weaknesses identified in this assessment. However, because of the
above condition, management’s assessment is that the Company’s internal controls over financial reporting were not effective
as of December 31, 2021.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">This annual report does not include an attestation
report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s
report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the Securities and
Exchange Commission that permit the Company to provide only management’s report in this annual report.</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0.25in; margin-bottom: 10pt"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 9B</b></td><td><b>Other Information</b></td></tr></tbody></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 1in"><b>Item 9C</b></td><td><b>Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></td></tr></tbody></table>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Not applicable</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</p>


<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>&nbsp;PART III</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0px">&nbsp;</td>
    <td style="width: 60px"><b>Item 10.</b></td>
    <td><b>Directors, Executive Officers and Corporate Governance</b></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The names of our current officers, directors and key
employees, as well as certain information about them, are set forth below:</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 23%; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt"><b>&nbsp;</b><i><span style="text-decoration: underline">Name</span></i></td>
    <td style="width: 6%; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center"><i><span style="text-decoration: underline">Age</span></i></td>
    <td style="width: 51%; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt"><i><span style="text-decoration: underline">Position with Corporation</span></i></td>
    <td style="width: 20%; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center"><i><span style="text-decoration: underline">Director Since</span></i></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt">Paul Mann</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center">46</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt">Chairman of the Board</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center">2021</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt">Manuel Iglesias</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center">67</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt">Director, President (Chief Executive Officer; Chief Financial Officer)</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center">2020</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt">Steven A. Horowitz</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center">62</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt">Director</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center">2021</td></tr>
  <tr style="background-color: white">
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt">Robert Brantl</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center">67</td>
    <td style="vertical-align: bottom; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt">Secretary</td>
    <td style="vertical-align: top; padding-right: 5.4pt; padding-bottom: 4pt; padding-left: 5.4pt; text-align: center">--</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 10pt 0; text-align: justify; text-indent: 0.5in">Directors hold office until
the annual meeting of the Corporation’s stockholders and the election and qualification of their successors. Officers hold office,
subject to removal at any time by the Board, until the meeting of directors immediately following the annual meeting of stockholders
and until their successors are appointed and qualified.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">&nbsp;Information concerning the directors and
officers of the Corporation follows:</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><i><span style="text-decoration: underline">Paul Mann</span></i>.&nbsp;Mr. Mann has been
appointed to the Board in order that he may contribute his expertise and experience with investment in the healthcare and biotechnology
industries. Mr. Mann is the Chairman of Varian Biopharmaceuticals, Inc., which was both acquired and sold by Healthtech Solutions during
2021. Since 2020 Mr. Mann has been engaged as a consultant and analyst for DSAM Partners providing investment advice relating to the healthcare
industry. From 2018 to 2020, Mr. Mann was employed as the Chief Financial Officer of Polarity TE, Inc. (NASDAQ: PTE), a biotechnology
company. From 2011 to 2018 Mr. Mann was employed as portfolio manager or analyst by, in succession, UBS, Lodestone Natural Resources,
Soros Fund Management and Highbridge Capital. Between 2000 and 2011 Mr. Mann spent 11 years as a sellside analyst at Morgan Stanley and
Deutsch Bank. Mr. Mann has been a member of the Board of Directors and Chairman of the Audit Committee of Abeona Therapeutics Inc. since
2020. In 1998 Mr. Mann graduated from Cambridge University with an M.A. (Cantab) and M. Eng. after studying Natural Sciences and Chemical
Engineering. He is a CFA Charterholder.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><i><span style="text-decoration: underline">Manuel
Iglesias</span></i><b>.</b>&nbsp;Mr. Iglesias participated in the organization of MediScan in 2018, and has served as its President and
Chief Operating Officer since that time. My. Iglesias also served as Chief Executive Officer of Mediscan from its organization until
May 2020. Mr. Iglesias has practiced law since 1980, most recently (since 2009) as sole member of Manuel E. Iglesias P.A. Mr.
Iglesias' practice focuses on business law, mergers and acquisitions, securities and health care. From 2007 until May 2018 Mr.
Iglesias served as President, CEO and a member of the Board of Directors of Hygea Holdings Corp., which provided primary care
medical services. From 2012 until 2016, Hygea Holdings Corp. filed reports with the Securities and Exchange Commission pursuant to
Section 15(d) of the Securities Exchange Act. In March of 2020, twenty-two months after Mr. Iglesias resigned from its management,
Hygea Holdings Corp. petitioned for relief under Chapter 11 of the U.S. Bankruptcy Code. From 2017 to 2019 Mr. Iglesias also served
on the Board of Directors of Organicell Regenerative Medicine Inc., which files reports pursuant to Section 12(g) of the Securities
Exchange Act. Mr. Iglesias served as the National Chairman of the Republican National Lawyers Association from December 2018 to
December 2020. Mr. Iglesias was awarded an MBA degree by the University of Chicago in 1981 and a J.D. degree by the University of
Chicago in 1979. Mr. Iglesias also received a Bachelor Degree in Foreign Service from the Georgetown University School of Foreign
Service in 1976.</p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><i><span style="text-decoration: underline">Steven A. Horowitz</span></i>.&nbsp;Mr. Horowitz
has been appointed to the Board in order that he may contribute his many years of experience as a business advisor and financial analyst.
Since 2015, Mr. Horowitz has been employed as a Managing Member of Horowitz &amp; Rubenstein, LLC, a law firm focused on business development
and financial management. From 2007 until 2015, Mr. Horowitz was the Managing Member of Horowitz Consulting Group, LLC, which provided
business consulting services. In 1984 Mr. Horowitz was awarded a J.D. degree by the Maurice A. Deane School of Law at Hofstra University.
In 1989, Mr. Horowitz was awarded a Master of Business Administration degree with a concentration in Public Accounting, by the Frank G.
Zarb School of Business at Hofstra University.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in"><i><span style="text-decoration: underline">Robert Brantl</span></i><b>.</b>&nbsp;Mr.
Brantl served as the sole officer and director of Healthtech Solutions from July 2017 until September 4, 2020 and is currently the Corporate
Secretary. Since 1980, Mr. Brantl has been employed as an attorney, licensed to practice law in the State of New York. He has been a sole
practitioner, specializing in matters of securities regulation and corporate finance, since 1998. Mr. Brantl was awarded a J.D. degree
by the Harvard Law School in 1979.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i><span style="text-decoration: underline">Audit Committee</span></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The Board of Directors has not appointed an
Audit Committee. The functions that would be performed by an Audit Committee are performed by the Board of Directors. The Board of Directors
has determined that Paul Mann possesses the qualifications to serve as an “audit committee financial expert” by reason of
his prior experience in financial analysis.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i><span style="text-decoration: underline">Code of Ethics</span></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The Company has not adopted a formal code of
ethics applicable to its executive officers because there are only two executive officers. As the size of management expands, the Board
of Directors intends to adopt a code of ethics for the Company.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i><span style="text-decoration: underline">Director Independence</span></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Of the three current directors, one (Steven
Horowitz) is independent as the term "independent" is defined by the rules of the NYSE American.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i><span style="text-decoration: underline">Section 16(a) Beneficial Ownership Reporting Compliance</span></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The following officers, directors or beneficial
owners of more than 10% of the Company’s common stock failed to file on a timely basis the reports identified below that were required
by Section 16(a) of the Exchange Act during the year ended December 31, 2020:</p>




<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="width: 6%">&nbsp;</td>
    <td style="text-align: center; width: 6%"><span style="font-family: Symbol">·</span></td>
    <td>Manuel Iglesias - failed to file Form 3 and one Form 4.</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Symbol">·</span></td>
    <td>Robert Brantl - failed to file one Form 4.</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>Item 11. Executive Compensation</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Healthtech Solutions (including Medi-Scan, Inc.
on a pro forma basis for periods prior to the acquisition of Medi-Scan by Healthtech Solutions in November 2020) paid compensation for
services as an officer to only one persons on a continuing basis during 2021 and 2020. (Excluded are payments made to two individuals
who served as executive officers of Healthtech Solutions for brief periods of 2021, one from May until September and one from July until
September.) The table below sets forth the annual compensation paid or accrued by the Company for payment to that individual during the
Company's last two fiscal years.</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="3">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Fiscal</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i><span style="text-decoration: underline">Year</span></i></p></td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="3">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&nbsp;</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i><span style="text-decoration: underline">Salary(1)</span></i></p></td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="3">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&nbsp;</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i><span style="text-decoration: underline">Bonus</span></i></p></td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="3">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Stock</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i><span style="text-decoration: underline">Awards</span></i></p></td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="3">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Option</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i><span style="text-decoration: underline">Awards</span></i></p></td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="3">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Other</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i><span style="text-decoration: underline">Compensation</span></i></p></td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="3">
    <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&nbsp;</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Total</i></p></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 38%; padding-left: 5.4pt"><span style="font-size: 11pt">Manuel Iglesias</span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 4%; text-align: right"><span style="font-size: 11pt">2021</span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><span style="font-size: 11pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="font-size: 11pt">100,000</span></td>
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 4%; text-align: right">—&nbsp;&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 5%; text-align: right">(2)&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 5%; text-align: right">—&nbsp;&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 10%; text-align: right">—&nbsp;&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><span style="font-size: 11pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="font-size: 11pt">80,000</span></td>
    <td style="width: 1%">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 5.4pt">&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 11pt">2020</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 11pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 11pt">80,000</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 11pt">—&nbsp;&nbsp;</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 11pt">—&nbsp;&nbsp;</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 11pt">—&nbsp;&nbsp;</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 11pt">—&nbsp;&nbsp;</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 11pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 11pt">80,000</span></td>
    <td>&nbsp;</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; color: #262626"><b>_____________________________</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0 10pt 19.45pt; text-align: justify; text-indent: -19.45pt"><span style="color: #262626">(1)</span>
Represents payments of $10,000 per month commencing in May 2020 and ending in November 2021 made to the law firm of Manuel E. Iglesias,
P.A. as compensation for Mr. Iglesias' services as an executive officer.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0 10pt 19.45pt; text-align: justify; text-indent: -19.45pt">(2) On July
19, 2021 Healthtech Solutions awarded 500,000 shares of restricted stock to The Manuel E. Iglesias Trust, of which Mr. Iglesias is the
beneficiary. The shares will vest over three years of Mr. Iglesias’ employment.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; color: #262626"><b><i>Employment Agreements</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Richard Parker</span></i>. Medi-Scan executed a
Chief Research Officer Agreement dated December 18, 2018 with 6 Sigma, LLC, whose manager is Richard Parker. The Agreement provides that
Mr. Parker will be designated Chief Research Officer of Medi-Scan, responsible for supervising the fulfillment of Medi-Scan's research
and development programs. In particular, subject to approval of Medi-Scan's Chief Operating Officer, Mr. Parker is authorized to supervise
Medi-Scan's research and development personnel, and to pursue such research projects as are determined by the COO. The Agreement provides
for base compensation of $72,000 per year, and provided Mr. Parker a dilutable 25% interest in Medi-Scan. The Agreement may be terminated
by Medi-Scan for cause and by Mr. Parker at will.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">All of our other officers serve on an at-will
basis.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; color: #262626"><b><i>Compensation of Directors</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">In July 2021, the Company entered into a
Director Agreement with Steven A. Horowitz, which is applicable throughout his tenure on the Board. The Company agreed to pay Mr.
Horowitz a fee for his service of $50,000 per year, payable at Mr. Horowitz's discretion in cash or common stock at market value. In
addition, upon execution of the Director Agreement, the Company awarded 500,000 shares of restricted common stock to Mr. Horowitz,
which will vest over a three year period of service on the Board. The award agreement provides that whenever Mr. Horowitz is
re-elected to the Board at an annual meeting of the shareholders, the Company will grant him additional restricted shares equal to
0.25% of the fully diluted outstanding shares.</p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">In July 2021, the Company entered into a Director
Agreement with Paul Mann, which is applicable throughout his tenure on the Board. The Company agreed to pay Mr. Mann a fee for his service
of $50,000 per year, payable at Mr. Mann's discretion in cash or common stock at market value. In addition, upon execution of the Director
Agreement, the Company awarded 500,000 shares of restricted common stock to Mr. Mann, which will vest over a three year period of service
on the Board. The award agreement provides that whenever Mr. Mann is re-elected to the Board at an annual meeting of the shareholders,
the Company will grant him additional restricted shares equal to 0.25% of the fully diluted outstanding shares.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in; color: #262626">In November 2021 Healthtech
Solutions issued 1,500,000 shares of common stock to each of its two non-executive directors in compensation for services.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i>Equity Grants</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Healthtech Solutions, Inc. has not adopted any
equity grant program.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0"><b>Item 12. Security Ownership of Certain Beneficial Owners and
Management</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 2in"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The following table sets forth information known
to us with respect to the beneficial ownership of each class of our voting stock as of the date of this registration statement by the
following:</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td style="width: 24px">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center; width: 24px"><span style="font-family: Symbol">·</span></td>
    <td>each shareholder known by us to own beneficially more than 5% of our common stock,</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Symbol">·</span></td>
    <td>Manuel Iglesias, our Chief Executive Officer,</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Symbol">·</span></td>
    <td>each of our directors, and</td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Symbol">·</span></td>
    <td>all directors and executive officers as a group.</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in">There are 66,965,933 shares of our common stock
issued and outstanding and 110,520 shares of our Series A Preferred Stock issued and outstanding on the date of this Report. Each share
of Series A Preferred Stock is convertible by its holder into 50 shares of common stock after May 31, 2024 and carries voting rights equal
to those carried by 50 shares of common stock. Healthtech Solutions, Inc. does not have any other class of stock outstanding. Except as
otherwise indicated, we believe that the beneficial owners of the common stock listed below have sole voting power and investment power
with respect to their shares, subject to community property laws where applicable. Beneficial ownership is determined in accordance with
the rules of the Securities and Exchange Commission.</p>


<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr>
    <td style="border: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td colspan="2" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt"><i>Common Stock</i></span></td>
    <td colspan="2" style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: top; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt"><i>Series A Preferred</i></span></td>
    <td style="border-bottom: Black 1pt solid">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 31%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><i>Name of</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt"><i>Beneficial Owner</i></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 15%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Amount and Nature of</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><i>Beneficial Ownership<sup>(1)</sup></i></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Percentage</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><i>of Class</i></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 15%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Amount and Nature of</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><i>Beneficial Ownership<sup>(1)</sup></i></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>Percentage</i></p>
    <p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><i>of Class</i></p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 13%; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt"><i>Total Voting Power</i></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="font-size: 11pt">Manuel Iglesias<sup>(2)</sup></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 11pt">129,309</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">0.2%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">3,137</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">2.8%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">0.4%</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="font-size: 11pt">Steven Horowitz<sup>(3)</sup></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 11pt">2,336,199</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">3.5%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">17,252</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">15.6%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">4.4%</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="font-size: 11pt">Paul Mann<sup>(4)</sup></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 11pt">1,500,000</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">2.2%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">--</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">--</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">2.1%</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="font-size: 11pt">All officers and directors as a group (4 persons)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 11pt">4,965,508</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">7.4%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">20,389</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">18.4%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">8.3%</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="font-size: 11pt">Richard F. Parker &amp; Charlotte B. Parker Revocable Living Trust<sup>(5)</sup></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 11pt">7,462,270</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">11.1%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">--</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">--</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">10.3%</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="font-size: 11pt">Exeter Life LLC<sup>(6)</sup></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 11pt">711,199</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">1.1%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">17,252</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">15.6%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">2.2%</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="font-size: 11pt">Jonathan Leinwand<sup>(7)</sup></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: right"><span style="font-size: 11pt">--</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center">&nbsp;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">43,946</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">39.8%</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 11pt">3.0%</span></td></tr>
  </tbody></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">_________________________________________</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt">
<tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">(1)</td><td>Ownership is of record and beneficial unless otherwise noted. </td></tr>
</tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">(2)</td><td>Shares attributed to Mr. M.E. Iglesias are owned by Manuel E. Iglesias Trust, of which Mr. Iglesias is beneficiary. The Table does
not reflect 500,000 shares of restricted common stock issued to Mr. Iglesias, which will vest during the first three years of his employment.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">(3)</td><td>Includes 711,199 shares of common stock and 17,252 shares of Series A Preferred Stock owned by Exeter Life, LLC., of which Mr. Horowitz
serves as Manager. Also includes 125,000 shares of common stock owned by Horowitz &amp; Rubenstein, LLC, of which Mr. Horowitz is a Managing
Member. The Table does not reflect 500,000 shares of restricted common stock issued to Mr. Horowitz, which will vest during the first
three years of his tenure on the Board.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">(4)</td><td>The Table does not reflect (a) 500,000 shares of restricted common stock issued to Mr. Mann, which will vest during the first three
years of his tenure on the Board, or (b) 1,000,000 performance stock units which will vest on July 13, 2024</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">(5)</td><td>Richard F. Parker has voting and dispositional control over shares owned by the Trust.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">(6)</td><td>Steven Horowitz has voting control over shares owned by Exeter Life LLC.</td></tr></tbody></table>

<table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 6pt"><tbody><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 0.5in">(7)</td><td>Mr. Leinwand controls the Series A shares as voting trustee appointed by Keystone Capital Partners.</td></tr></tbody></table>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b>Item 13. &nbsp;&nbsp;Certain Relationships and Related Transactions
and Director Independence</b></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i><span style="text-decoration: underline">Related Party Transactions</span></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Director Agreements and Compensation to Directors</i></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In July 2021, the Company entered into a Director Agreement with
Steven A. Horowitz, which is applicable throughout his tenure on the Board. The Company agreed to pay Mr. Horowitz a fee for his service
of $50,000 per year, payable at Mr. Horowitz's discretion in cash or common stock at market value. In addition, upon execution of the
Director Agreement, the Company awarded 500,000 shares of restricted common stock to Mr. Horowitz, which will vest over a three year
period of service on the Board. The award agreement provides that whenever Mr. Horowitz is re-elected to the Board at an annual meeting
of the shareholders, the Company will grant him additional restricted shares equal to 0.25% of the fully diluted outstanding shares.</p>

<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In July 2021, the Company entered into a Director Agreement with
Paul Mann, which is applicable throughout his tenure on the Board. The Company agreed to pay Mr. Mann a fee for his service of $50,000
per year, payable at Mr. Mann's discretion in cash or common stock at market value. In addition, upon execution of the Director Agreement,
the Company awarded 500,000 shares of restricted common stock to Mr. Mann, which will vest over a three year period of service on the
Board. The award agreement provides that whenever Mr. Mann is re-elected to the Board at an annual meeting of the shareholders, the Company
will grant him additional restricted shares equal to 0.25% of the fully diluted outstanding shares.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In November 2021, in consideration of services rendered, Healthtech
Solutions issued 1,500,000 shares of its common stock to each of Messrs. Horowitz and Mann.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Consulting Agreement with Mr. Mann</i></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In July 2021, the Company also entered into a Consulting Agreement
with Paul Mann, pursuant to which Mr. Mann will provide guidance to the research and development activities carried out by the Company.
In compensation for those services, the Registrant issued to Mr. Mann one million (1,000,000) performance restricted share units ("PSUs").
On July 13, 2024, if the Consulting Agreement remains in force, the Company will issue shares of common stock in settlement of the PSUs.
The number of shares to be issued will be determined on the basis of the market price for the common stock at that time or the Company’s
market cap at that time.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><i>Legal Fees and Compensation to Mr. Brantl</i></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">For legal services rendered by Robert Brantl and expenses incurred
as counsel to Healthtech Solutions during 2021, Healthtech Solutions accrued $245,152. Mr. Brantl was the sole officer and director of
Healthtech Solutions until September 4, 2020, and has served as Secretary of Healthtech Solutions since September 4, 2020.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">In November 2021, in consideration of services rendered, Healthtech
Solutions issued 1,000,000 shares of its common stock to Mr. Brantl.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt">Except as described above, there have been no transactions since
January 1, 2021, or any currently proposed transaction, in which Healthtech Solutions or its subsidiaries was or is to be a participant
and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of the total assets of Healthtech Solutions
at year-end for the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest.
&nbsp;</p>


<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i><span style="text-decoration: underline">Director Independence</span></i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">The Board of Directors has determined that Steven
A. Horowitz is the only member of our Board of Directors who is independent, as “independent” is defined in the rules of the
NYSE American.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>Item 14. Principal Accountant Fees and Services</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prager Metis CPAs, LLC has been the independent registered
public accountant for the Company since June 26, 2020.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Audit Fees</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prager Metis CPAs, LLC billed $45,000 in connection
with the audit of the Company's financial statements for the year ended December 31, 2021. Prager Metis CPAs, LLC billed $18,500 in connection
with the audit of the Company's financial statements for the year ended December 31, 2020, billed $4,500 in connection with the audit
of the Company’s financial statements for the year ended June 30, 2020, and billed $15,000 in connection with the audit of the
financial statements of Medi-Scan, Inc.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Audit-Related Fees</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prager Metis CPAs, LLC did not bill the Company for
any Audit-Related fees in fiscal 2021 or 2020.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>Tax Fees</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prager Metis CPAs, LLC did not bill the Company for
any professional services rendered for tax compliance, tax advice and tax planning in fiscal 2021 or 2020.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><b><i>All Other Fees</i></b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prager Metis CPAs, LLC did not bill the Company for
any other fees in fiscal 2021 or 2020.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">It is the policy of the Company that all services,
other than audit, review or attest services, must be pre-approved by the Board of Directors.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b>Item 15. &nbsp;&nbsp;Exhibits and Financial Statement Schedules</b></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 10pt"><b><i><span style="text-decoration: underline">Exhibits</span></i></b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 12%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/1307624/000126246320000095/ex3a.htm" tabindex="18">3-a</a></td>
    <td style="width: 88%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">Restated Articles of Incorporation filed on July 12, 2004<sup>(1)</sup></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/1307624/000126246320000095/ex3a1.htm" tabindex="18">3-a(1)</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Articles of Amendment to Articles of Incorporation filed on September 27, 2006<sup>(1)</sup></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/1307624/000126246320000095/ex3a2.htm" tabindex="18">3-a(2)</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Articles of Amendment to Articles of Incorporation filed on June 28, 2019<sup>(1)</sup></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/0001307624/000126246321000053/ex3a3.htm" tabindex="18">3-a(3)</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Articles of Amendment to Articles of Incorporation filed on November 6, 2020<sup>(2)</sup></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/1307624/000126246320000464/ex31.htm" tabindex="18">3-a(4)</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Articles of Amendment to Articles of Incorporation filed on November 16, 2020<sup>(3)</sup></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/1307624/000126246321000043/ex3a.htm" tabindex="18">3-a(5)</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Articles of Amendment to Articles of Incorporation filed on February 16, 2021<sup>(4)</sup></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246321000151/ex31.htm" tabindex="18">3-a(6)</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Articles of Amendment to Articles of Incorporation filed on March 31, 2021<sup>(5)</sup></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246321000573/ex3a.htm" tabindex="18">3-a(7)</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Articles of Amendment to Articles of Incorporation filed on November 12, 2021<sup>(6)</sup></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/1307624/000126246320000095/ex3b.htm" tabindex="18">3-b</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Bylaws - as amended on June 25, 2019<sup>(1)</sup></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246322000054/ex4.htm" style="-sec-extract: exhibit" tabindex="18">4(vi)</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Description of Common Stock</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="http://www.sec.gov/Archives/edgar/data/1307624/000126246320000464/ex101.htm" tabindex="18">10-a</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Technology Assignment Agreement dated December 18, 2018 among Richard Parker, 6 Sigma LLC and Medi-Scan, LLC<sup>(3)</sup></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246321000318/ex10a.htm" tabindex="18">10-b</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Director Agreement dated July 2, 2021 between Healthtech Solutions, Inc. and Steven A. Horowitz<sup>(7)</sup></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246321000322/ex10a.htm" tabindex="18">10-c</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Director Agreement dated July 13, 2021 between Healthtech Solutions, Inc. and Paul Mann<sup>(8)</sup></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246321000322/ex10b.htm" tabindex="18">10-d</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Consulting Agreement dated July 13, 2021 between Healthtech Solutions, Inc. and Paul Mann<sup>(8)</sup></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246322000023/ex10b.htm" tabindex="18">10-e</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span>Operations Agreement dated January 31, 2022 among Healthtech Solutions, Inc., Healthtech Wound Care, Inc., Predictive Biotech, Inc. and Predictive Technology Group, Inc.<sup>(9)</sup></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246322000054/ex21.htm" style="-sec-extract: exhibit" tabindex="18">21</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span>Subsidiaries</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246322000054/ex31.htm" style="-sec-extract: exhibit" tabindex="18">31.1</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="color: #262626">Rule 13a-14(a) Certification of Principal Executive and Principal Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><a href="https://www.sec.gov/Archives/edgar/data/1307624/000126246322000054/ex32.htm" style="-sec-extract: exhibit" tabindex="18">32.1</a></td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt"><span style="color: #262626">Rule 13a-14(b) Certification of Principal Executive and Principal Financial Officer</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">101.INS</td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Inline XBRL Instance Document</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">101.SCH</td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Inline XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">101.CAL</td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">101.DEF</td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">101.LAB</td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">101.PRE</td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">104</td>
    <td style="padding-right: 5.4pt; padding-bottom: 6pt; padding-left: 5.4pt">Cover Page Interactive Data File (formatted as Inline XBRL) and contained in Exhibit 101</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 7%; padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(1)</span></td>
    <td style="width: 2%; padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="width: 91%; padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">Filed as an exhibit to the Registration Statement on Form 10 filed on March 19, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(2)</span></td>
    <td style="padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">Filed as an exhibit to the Annual Report on Form 10-K for the year ended December 31, 2020</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(3)</span></td>
    <td style="padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.5in; text-indent: -0.5in"><span style="color: #262626">Filed as an exhibit to the Current Report on Form 8-K filed on November 16, 2020.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(4)</span></td>
    <td style="padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="padding-top: 6pt; padding-bottom: 6pt; padding-left: 0.5in; text-indent: -0.5in"><span style="color: #262626">Filed as an exhibit to the Current Report on Form 8-K filed on February 22, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(5)</span></td>
    <td style="padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">Filed as an exhibit to the Current Report filed on April 1, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(6)</span></td>
    <td style="padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">Filed as an exhibit to the Current Report filed on November 18, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(7)</span></td>
    <td style="padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">Filed as an exhibit to the Current Report filed on July 2, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(8)</span></td>
    <td style="padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">Filed as an exhibit to the Current Report filed on July 13, 2021.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">(9)</span></td>
    <td style="padding-top: 6pt; padding-bottom: 6pt">&nbsp;</td>
    <td style="padding-top: 6pt; padding-bottom: 6pt"><span style="color: #262626">Filed as an exhibit to the Current Report filed on February 3, 2022.</span></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0px">&nbsp;</td>
    <td style="width: 96px"><b>Item 16.</b></td>
    <td><b>Form 10-K Summary</b></td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 12pt/12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 49.5pt">In accordance with Section 13 or 15(d) of the Exchange
Act, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 43%; padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td style="padding: 12pt 5.4pt; width: 57%; text-indent: -4.1pt"><b>Healthtech Solutions, Inc.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>By: <span style="text-decoration: underline">/s/ Manuel E. Iglesias</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-top: 12pt; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</td>
    <td>Manuel E. Iglesias, Chief Executive Officer</td></tr>
  </tbody></table>
<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><b>&nbsp;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 49.5pt">In accordance with the Exchange Act, this Report has
been signed below on April 15, 2022 by the following persons, on behalf of the Registrant and in the capacities and on the dates indicated.</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Manuel E. Iglesias </span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">Manuel E. Iglesias, Director</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">Chief Executive Officer (Principal Executive Officer; Principal Financial
and Accounting Officer)</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<span style="text-decoration: underline">/s/ Steven A. Horowitz </span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">Steven A. Horowitz, Director</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">/s/ Paul Mann </span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">Paul Mann, Director</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>




<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 57; Options: Last -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tbody><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&nbsp;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&nbsp;</td></tr></tbody></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>




<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->

</body>
</html>